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SUMMARY 
CHIP, encoded by the gene STUB1, is a central component of cellular protein homeostasis. It 
acts as a co-chaperone of HSC/HSP70 and HSP90 to modulate their activity and as an E3 ligase, 
tagging chaperone-bound misfolded proteins with ubiquitin and thereby leading to their 
degradation. Mutations in STUB1 cause the neurological disorder autosomal recessive cerebellar 
ataxia type 16 (SCAR16), characterized by atrophy of the cerebellum, brain stem and spinal cord, 
but patients also show widespread neurodegeneration with symptoms of epilepsy, cognitive 
impairment and hypogonadism.   
CHIP-/- mice present with cerebellar atrophy manifesting in distinct motor but also cognitive 
impairment phenotypes and aging-induced cardiac hypertrophy. 20% of CHIP-/- mice die post-
natally and 100% die upon thermal challenge. Furthermore, they present with decreased stress 
tolerance, increased oxidative damage and increased insoluble protein aggregate levels. In vitro 
data supports this line of evidence by showing a higher vulnerability to stress and an impaired 
heat shock response (HSR) in STUB1-/- cells.   
To further understand the pathophysiology of SCAR16 and the effect of mutant STUB1 on the 
HSR, we first analyzed HSR induction and recovery in patient-derived fibroblasts. In accordance 
with previously published results from mesodermal cell lines, we saw a trend towards lower 
nuclear HSF1 levels after heat shock in patient cells compared to control cells which translated 
into lower HSP transcript levels upon induction. Furthermore, we detected an impaired HSR 
recovery on protein level, indicated by remaining high levels of HSP70. Interestingly, mutant 
CHIP did not alter cell viability of fibroblasts upon prolonged heat stress, but a CHIP-
independent high susceptibility of fibroblasts to heat-inducible cell death was observed in all 
lines.   
As SCAR16 primarily affects the central nervous system, we next attempted to determine the 
relevance of CHIP in the HSR of cortical neurons. For this purpose and for ideal in vitro disease 
Page | 2 
 
modeling, we generated induced pluripotent stem cells from fibroblasts of 3 SCAR16 patients 
and 3 healthy controls. Furthermore, we generated a homozygous knockout by CRISPR/Cas9-
mediated genome editing from one isogenic control line by dual cleavage of DNA and deletion 
of 155 base pairs, thereby generating a premature stop codon at amino acid position 99. The 
homozygous knockout state was verified on transcript and protein level. All generated iPSC lines 
were validated for genomic integrity by exclusion of plasmid integration, SNP array analysis, 
resequencing of the mutation site and STR analysis. To verify the pluripotency of iPSCs, we 
assessed the expression of pluripotency-related intra- and extracellular proteins and the 
transcript levels of pluripotency-related genes and examined the potential of iPSCs to 
spontaneously differentiate into cells of all three germ layers. The generated iPSCs of 3 SCAR16 
patients, 3 healthy controls and the STUB1(-/-) line were differentiated into cortical neurons 
specific for layer V of the neocortex with high homogeneity of CTIP2/TUJ-positive cells. In 
contrast to our findings in patient-derived fibroblasts, we did not see any distinctive 
(dys)functional CHIP-related effect on HSF1 translocation from the cytoplasm to the nucleus 
upon heat shock, as shown by cellular fractionation analysis. Yet, we observed an increased HSR 
induction on transcript level that, surprisingly, did not translate into any changes on HSP70 
protein level. However, unstressed neurons of both patients and controls already expressed high 
levels of HSP70 compared to fibroblasts. Analyzing cell viability of cortical neurons upon 
prolonged heat stress, we saw a surprising resistance of neurons to this stress stimulus compared 
to fibroblasts, again regardless of CHIP mutations.   
To gain more insights into the effect of dysfunctional CHIP in cortical neurons, we next 
performed proteomic analysis and observed dysfunctional protein (re)folding and a higher basal 
oxidative stress level in patients.  
Our results question the role of impaired HSR in SCAR16 neuropathology and highlight cell-
specific differences of the HSR, emphasizing the need of careful selection of proper disease 
models. 
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SYNOPSIS 
1. Rare neurological disorders 
Cerebellar ataxias (CAs) and hereditary spastic paraplegias (HSPs) are rare neurological 
disorders with a prevalence of 1-5 or 1-10 per 100.000 individuals, respectively (Ruano et al., 2014). 
Both are monogenic disorders with huge genetic heterogeneity: more than 100 genes have been 
identified to cause CAs and more than 80 for HSP with an autosomal dominant, recessive, X-
linked and mitochondrial trait of inheritance in both diseases (Hedera, 2018; Bird, 2019).  
Apart from genetic heterogeneity, CAs are also clinically diverse neurological disorders 
characterized by a loss of coordination (ataxia) leading to unsteadiness of gait and stance, 
impaired fine motor skills, slurred speech and diplopia due to cerebellar deficits. Apart from the 
cerebellum, degeneration may also occur in the brainstem, the corticospinal and spinocerebellar 
tracts as well as the dorsal columns of the spinal cord, the peripheral nerves but also the cerebral 
cortex. This extends the phenotypic spectrum to extracerebellar symptoms such as spasticity, 
weakness, sensory deficits or cortical symptoms like seizures and cognitive impairment. Some 
subtypes of CA affect other organs as well, leading to cataract, cardiomyopathy or 
hypogonadism. Age of onset ranges from childhood to adulthood (reviewed by Kuo, 2019; Manto 
et al., 2019). Pathophysiological mechanisms involved in CAs include inter alia proteotoxicity, 
RNA toxicity, impaired bioenergetics, ion channel dysfunction and metabolic defects (reviewed 
by Klockgether et al., 2019). Apart from a few metabolic CAs, no causative treatment is available 
so the current therapy is focused on physiotherapy, occupational therapy and speech therapy 
(reviewed by Kuo, 2019; Manto et al., 2019).  
Hereditary spastic paraplegia is characterized by the axonal degeneration of upper motor 
neurons with highly variable severity and age of onset, ranging from early childhood to late 
adulthood. Patients with pure HSP present with progressive lower limb spasticity and weakness 
leading to gait impairment while complicated forms can also include inter alia cognitive 
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impairment, optic atrophy, cerebellar ataxia, peripheral neuropathy or seizures. 
Pathophysiological mechanisms range from intracellular axonal trafficking defects and 
mitochondrial dysfunctions to impaired endoplasmic reticulum (ER) shaping and function and 
alterations of membrane shaping and trafficking (Blackstone et al., 2011; Schule et al., 2011; Lo 
Giudice et al., 2014). With rare exceptions, treatment is also limited to physiotherapy and 
symptomatic reduction of muscle spasticity only (Schule et al., 2016).  
Both diseases share many symptoms and mechanisms: many complex forms of HSP also present 
with ataxia (e.g. SPG5, SPG7, SPG11, SPG46) and many ataxias go along with spasticity as well 
(e.g. ARSACS, SCA1, SCA3, SCA7)(reviewed by Manto et al., 2019). Understanding the disease 
mechanisms is the key to finding a treatment or cure for the disease.  
2. Disease modeling of neurological and neurodegenerative diseases 
Studying neurological disorders remains a challenge due to the inaccessibility of the diseased 
brain for analysis. Patient-derived brain tissue can only be analyzed post mortem which poses 
problems with preservation of DNA, RNA, proteins and lipids but also precludes the study of the 
disease onset and the attributed early damages. To understand the pathology of these diseases 
therefore requires an appropriate disease model in vitro or in vivo. Both systems have their 
advantages and disadvantages.  
While in vitro models allow faster data acquisition and easier reproducibility of results, they are 
often based on overexpression or knockdown of genes in immortalized cell lines which are 
cheap, readily accessible and easy to manipulate genetically. Those cell lines, though, are often 
derived from cancers and therefore contain numerous genomic aberrations and are usually 
highly proliferative which does not provide an adequate model for non-proliferating post-
mitotic neurons. In addition to that, overexpression of pathogenic genes may lead to an artificial 
cell signaling. While primary cells isolated from rodents do show cell specificity, they are usually 
difficult to be maintained and expanded, limiting the accessibility and scalability. In vivo rodent 
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models in turn have the advantage of a complex multi-organ system with many conserved genes 
across species, but they usually fail to reproduce pathological findings of neurodegenerative 
diseases, rely on human protein overexpression and are very time- and resource-consuming, 
especially for drug screening. Although both approaches have contributed to elucidating key 
pathological mechanisms of diseases, findings can often not be translated to human situations 
(McGonigle et al., 2014; Genc et al., 2019). A human model organism of the diseased cell type 
might therefore help to decipher key pathological events of neurological disorders, allowing for 
target identification, drug screening and therapy development that can further be tested in other 
more complex systems. The basis for this new test system was provided by the first generation 
of induced pluripotent stem cells from somatic cells in 2006 (Takahashi et al., 2006).   
3. Induced pluripotent stem cells  
Induced pluripotent stem cells (iPSCs) are characterized by two unique features that all stem 
cells retain: the capacity of self-renewal and the capability of differentiation into specialized cell 
types. iPSCs as the name implies are pluripotent i.e. they possess the ability to differentiate into 
all cells of the three germ layers opposed to totipotent (ability to differentiate into cells of the 
whole organism, including extra-embryonic tissues), multipotent (ability to differentiate into 
cells of one lineage) or oligopotent (ability to differentiate into few cell types) stem cells.  
The first established protocol to generate iPSCs from somatic cells, a process named 
reprogramming, was published by Takahashi and Yamanaka (2006) and was awarded the Nobel 
Prize only six years later. They generated iPSCs from mouse embryonic and human adult 
fibroblasts by retroviral delivery of the four transcription factors OCT3/4, KLF4, SOX2 and c-
MYC (Takahashi et al., 2006; Takahashi et al., 2007). OCT3/4 and SOX2 are transcription factors 
of the core transcriptional regulatory circuitry of pluripotency-related genes (Boyer et al., 2005), 
KLF4 functions as both tumor suppressor and oncogene and improves the efficiency of 
reprogramming (Dang et al., 2000; Takahashi et al., 2006) and c-MYC acts as a proto-oncogene 
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and enhances proliferation and transformation (Dang et al., 2006).  
These ‘first generation’ iPSCs resembled embryonic stem cells (ESCs) in morphology, 
proliferation and differentiation capacities. However, retroviral (as well as lentiviral) delivery of 
the transcription factors led to frequent integration into the host DNA, to silencing of some 
endogenous genes while other exogenous copies were not completely silenced or to carcinogenic 
action upon reactivation (c-MYC)(Takahashi et al., 2006; Okita et al., 2011). Furthermore, it was 
soon detected that these first iPSCs were only partially reprogrammed (Okita et al., 2007). This 
caused a flood of improved protocols for reprogramming in an integration-free system, ranging 
from adenoviral and episomal plasmid delivery to piggyback transposition, Cre-recombinase 
excisable viruses, direct delivery of proteins and synthetically modified mRNAs (reviewed by 
Malik et al., 2013). Furthermore, replacing c-MYC by its non-carcinogenic variant l-MYC or 
replacing both KLF4 and c-MYC by NANOG and LIN28 enhanced safety and efficiency (Yu et 
al., 2007; Viswanathan et al., 2008; Nakagawa et al., 2010). NANOG is a transcription factor of 
the core transcriptional regulatory circuitry of pluripotency-related genes, while LIN28 is an 
mRNA binding protein that blocks microRNA-mediated differentiation of ESCs, promoting 
proliferation and accelerated iPSC formation (Yu et al., 2007; Viswanathan et al., 2008; Hanna et 
al., 2009). Others have shown that efficiency can be increased by enhancers of epigenetic 
remodeling like sodium butyrate or valproic acid (Huangfu et al., 2008; Mali et al., 2010).  
Upon successful generation, clonal expansion and selection of iPSCs, genomic integrity and 
pluripotency needs to be verified before continuing with further analysis. For this purpose, we 
excluded chromosomal aberrations that might have occurred during reprogramming, verified 
the presence of the reported mutation in the patient’s original fibroblast and generated iPSC line 
and checked the non-integration of plasmids. Furthermore, to verify pluripotency, the 
expression of 1) alkaline phosphatase and 2) the transcription factors OCT3/4 and TRA1-81 was 
shown, 3) pluripotency-related transcript expression in a pattern similar to human embryonic 
stem cells (hESCs) and distinct to the original fibroblasts was verified and finally, 4) iPSCs were  
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shown to differentiate into cells of the three germ layers endoderm, mesoderm and ectoderm 
(Schuster et al., 2018, Fig. 1). While the latter was assessed earlier by injecting iPSCs into 
immunodeficient mice and analyzing the developing teratomas (Yamanaka et al., 2006), it is 
now sufficient to test the pluripotency of iPSCs via an embryoid body-based differentiation using 
defined media, a method initially described by Doetschman and colleagues for human 
embryonic stem cells (1985).  
Up to now, iPSCs for rodents and humans were generated from a range of somatic cell types 
from blood, liver, stomach, pancreas, brain, intestine and adrenal glands, but the most 
frequently used cell types are fibroblasts, PBMCs and keratinocytes due to their easy accessibility 
(reviewed by Stadtfeld et al., 2010). iPSCs allow many applications in the fields of drug 
development, disease modeling and tissue repair, due to their easy clonal expansion, the 
advantage of endogenous protein levels with the host’s genetic background and the potential to 
generate all cell types of the human body. These characteristics also qualify iPSCs as an ideal 
tool for modeling neurological disorders, with various differentiation protocols available that 
allow the generation of a defined cell type of interest, like specific neurons or astrocytes (Fig. 1). 
FIG. 1 | Generation of in vitro models for neurological disease modeling. Somatic cells such as fibroblasts from 
a patient or a healthy control can be reprogrammed to induced pluripotent stem cells (iPSCs) by the addition of the 
4 Yamanaka factors OCT3/4, SOX2, KLF4 and C-MYC. iPSCs can be differentiated into neural progenitors, which in 
turn can be differentiated to cells of the astrocytic, neuronal or oligodendroglial lineage. 
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3.1 Neuronal differentiation  
The mammalian neocortex consists of a six-layered structure with specialized cells with 
distinguishable morphological, neurochemical or electrophysiological properties in each layer. 
In general, all cortical cell types can be classified as either excitatory projection neurons or 
inhibitory interneurons. Intercortical connections are located in layer I to IV while neurons from 
layer V and VI signal to other brain areas. 
Neuronal differentiation of stem cells (for both ESCs and iPSCs) recapitulates in vivo 
corticogenesis. First protocols for neuronal differentiation were based on the generation of free-
floating embryoid bodies followed by adherent culture conditions with FGF2-guided 
differentiation into neural rosettes consisting of neuroepithelial cells (Zhang et al., 2001; Koch et 
al., 2009). Current methods usually utilize dual SMAD inhibition with the inhibitors noggin, 
dorsomorphin or LDN193189 together with SB431542 (Chambers et al., 2009; Kim et al., 2010). 
Noggin, dorsomorphin and LDN193189 all are potent BMP inhibitors, acting by blocking 
phosphorylation of SMAD1/5/8 and thereby preventing the transcription of pluripotency-
associated genes (Chambers et al., 2009; Kim et al., 2010). SB431542 blocks phosphorylation of 
the TGFß1 receptors ALK4/5/7 and SMAD2/3, leading to TGFß/Activin/Nodal pathway 
inhibition which is crucial for pluripotency maintenance (James et al., 2005; Smith et al., 2008; 
Xu et al., 2008). This dual inhibition increased the efficiency of neural induction to 80% PAX6+ 
cells, an early neuronal marker, compared to ~10% only for administration of a single compound 
(Chambers et al., 2009).  
Telencephalic neural progenitors can further be differentiated via dorsal or ventral progenitors 
into excitatory projection neurons or inhibitory interneurons, respectively (Kim et al., 2014a). 
The dorsal lineage is considered as the default pathway, but efficiency can be potentiated by 
retinoid signaling (Shi et al., 2012). Upon prolonged differentiation for more mature neurons, 
cortical neurons can specifically be induced by MAPK and γ-secretase inhibition via DAPT and 
PD0325901, leading to complete loss of ventral neural progenitor-specific markers (Crawford et 
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al., 2007; Eiraku et al., 2008). This induction can lead to the generation of both deep- and upper-
layer cortical neurons at 7 or 10 weeks of differentiation, respectively, with the spatio-temporal 
separation reminiscent of in vivo corticogenesis (Eiraku et al., 2008; Shi et al., 2012). For other 
neuronal cell types, specific patterning factors are needed. Protocols are currently available for 
a wide range of neuronal cell types, including cholinergic neurons, cortical projection neurons, 
midbrain dopaminergic neurons, striatal neurons, spinal motor neurons, Purkinje cells and 
serotonergic neurons. More recently, differentiation protocols for astrocytes, oligodendrocytes 
and microglia were developed and optimized (reviewed by McComish et al., 2018). For 
neurodegenerative disease modeling, the differentiation of iPSCs into candidate neural lineages 
is sometimes the key to recapitulating disease phenotypes.   
Purkinje cells would be the cell type of choice to model cerebellar ataxias in vitro, but their large 
size, complex morphology, unique firing pattern and extensive maturation period renders them 
difficult to generate. The first iPSC-derived Purkinje cells required co-cultivation with human 
fetal cerebellar slices (Wang et al., 2015). Needless to say, this impedes reproducibility in many 
laboratories around the world due to ethical constraints. An optimized and simplified protocol 
was published in 2018 that required extensive periods of cultivation and co-cultivation with 
mouse cerebellar progenitors (which did not work in the hands of Wang and colleagues (2015)), 
and still only yielded 10% Purkinje cells (Watson et al., 2018). Furthermore, the very limited 
number of published protocols for Purkinje cell differentiation and the fact that protocols were 
not reproduced by other labs emphasizes the difficulty of generating Purkinje cells from iPSCs 
and highlights the need for reproducible and less complex protocols.   
A great concern of all differentiation protocols still remains the low efficiency and the mentioned 
homogeneity of generated neurons. While dopaminergic neuronal protocols usually reach an 
efficiency of 10-30% of the desired cell type (Sanchez-Danes et al., 2012) and lower motor neuron 
differentiation generates 50-55% of Islet1-positive cells but always includes astrocytes (Reinhardt 
et al., 2013; Maury et al., 2015), the protocol from Shi and colleagues (2012) to generate cortical 
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projection neurons of layer V and VI with slight modifications (Rehbach et al., 2019) yielded 
100% TUJ+ and >75% cortical layer V marker CTIP2+ cells in our hands. This homogeneity of cells 
was further highlighted by transcript expression analysis: we compared transcript data of 
cortical neurons of 2 control lines and 2 SCAR16 patients to transcript data of the BrainSpan atlas 
(http://www.brainspan.org) of the human developing brain, from fetal to 1 year of age 
postmortem tissue. The gene signature of all 4 generated cortical neurons was very similar, with 
the most significantly enriched co-expressed gene set being the neocortex and subcortex at post 
conception week (pcw) 12 to 21 and with the strongest correlation at pcw 16 (Schuster et al., in 
preparation, Fig. 3). This underlines the homogeneity of generated cortical neurons but also 
emphasizes an important aspect and a major drawback of iPSC-based disease modeling: 
generated cell types usually resemble prenatal fetal cells, which might render the modeling of 
neurodegenerative diseases, usually occuring late in life, more difficult.   
However, while HSPs and SCAs are considered as neurodegenerative diseases, its causes are 
usually monogenic and therefore easier to analyze in vitro, compared to many sporadic forms of 
neurodegeneration. Furthermore, age of onset for many subtypes and many patients is already 
in early childhood. In addition to this, many forms of HSPs and SCAs are complex and not 
limited to one cell type, e.g. SCAR16 initially affects Purkinje cells with subsequent widespread 
neurodegeneration throughout the brain (Hayer et al., 2017), indicating an effect of mutation 
that is less specific to one neuronal cell type. This led us to the selection of a protocol that is 
generating a homogenous class of neurons with an easy and less time-consuming differentiation 
protocol (as described above).  
3.2 Disease modeling of neurodegenerative diseases using iPSC-
derived neurons  
The first iPSC lines from patients with neurodegeneration were described in 2008 (Dimos et al., 
2008), with more than 50 reports already being published in 2014 and numerous more thereafter, 
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including disease models of Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic 
lateral sclerosis (ALS), hereditary spastic paraplegias (HSPs) and spinocerebellar ataxias (SCAs) 
(reviewed by Hargus et al., 2014). Many groups reported pathological changes in iPSC-derived 
neurons and even found treatment options. iPSC-derived neurons from AD patients showed an 
accumulation of Aß oligomers, leading to ER and oxidative stress which was reverted by 
docosahexaenoic acid treatment (Kondo et al., 2013); iPSC-derived neurons from PD patients 
with LRRK2 mutations showed mitochondrial deficits associated with increased cell 
vulnerability which could be rescued by coenyzyme Q(10), rapamycin or GW5074 
administration (Cooper et al., 2012). Another study analyzed neuromuscular junction-like 
structures from iPSCs of spinal muscular atrophy patients and they showed impaired clustering 
of acetylcholine receptors, which could be ameliorated by valproic acid and antisense 
oligonucleotide treatment (Yoshida et al., 2015); and iPSC-derived neurons from ALS patients 
showed hypoexcitability, cytoplasmic FUS pathology and progressive axonal transport defects, 
all reverted by HDAC6 inhibition (Guo et al., 2017). Diseases with monogenic causes like HSP or 
SCAs are ideal for disease modeling as there is a direct causal relationship between mutation 
and disease.  
To analyze the fit of different cell types for disease modeling of motor neuron disorders (MNDs) 
like amyotrophic lateral sclerosis, hereditary spastic paraplegia, spinal muscular atrophy and 
other spasticity-related genes, we analyzed transcript expression of 168 disease-relevant genes 
in PBMCs, lymphoblasts, fibroblasts, iPSCs and iPSC-derived cortical neurons of 2 healthy 
controls (Hauser et al., in preparation). We showed that as expected, transcript expression 
strongly varied between different cell types of the same donor but varied little between the same 
cell type of different donors. Of all analyzed genes, 30% were expressed highest in cortical 
neurons, 24% in fibroblasts, 16% in lymphoblasts, 13% in iPSCs and 8% in PBMCs, while 9% were 
not expressed in any of the analyzed cell types (Hauser et al., in preparation, Fig. 3). This 
indicates that blood analysis for many subtypes of the disease is not appropriate while cortical 
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neurons and fibroblasts stand out as better disease models. Interestingly, transcript levels of 
MND-related genes with highest expression in neurons were 3-fold higher than the average 
transcript levels of all 4 other cell lines (compared to approximately 2-fold for fibroblasts).  
To be highlighted here are the two HSP-related genes REEP1 and SPAST that show remarkably 
higher levels in cortical neurons compared to all other cell types, with a fold change of 200-
20.000 for REEP1 and 5-10 for SPAST (Hauser et al., in preparation, Fig. 2, 4). Both genes are 
investigated in our lab; with generated iPSCs from SPG4 patients with mutations in SPAST 
(Hauser et al., 2016), Rehbach and colleagues (2019) identified reduced neurite outgrowth, 
increased growth cones and axonal swellings in iPSC-derived neurons in a neuronal subtype-
specific manner and with rescue by GW3965 treatment. Interestingly, axonal swellings are 
considered a pathological hallmark of HSP which further strengthens the usability of iPSC-
derived neurons in neurological disease modeling.  
Monogenic disorders are usually rare diseases with low incidence in the population. This limits 
tissue accessibility to study disease-relevant pathological changes in vitro. In addition to iPSCs, 
another technology highly enhanced the potential for proper disease modeling: genome editing 
by CRISPR/Cas9.  
4. CRISPR/Cas9-mediated genome editing  
Genome editing provides a tool for controlled inactivation or repair of a gene. This is often 
needed for proper disease modeling to either have a negative control of no remaining activity or 
to repair or insert mutations for an isogenic cell pair. Isogenic lines have the advantage of the 
identical genetic background with an exception of one particular gene which reduces the noise 
that is usually caused by varying genetic backgrounds. It thereby facilitates the detection of 
causative disturbances and the analysis of many large-scale methods like transcriptomics and 
proteomics.  
In the past, the techniques of choice for DNA editing were based on zinc finger nucleases (ZFNs) 
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and transcription activator-like effector nucleases (TALENs), both relying on sequence-specific 
DNA-binding modules linked to non-specific DNA nucleases that cleave DNA (reviewed by Gaj 
et al., 2013). The current method of choice for genome editing was first described in 2013 and is 
based on the system of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) 
and CRISPR-associated protein (Cas)(Cong et al., 2013; Mali et al., 2013). CRISPR/Cas was 
discovered in eubacteria and archaea as a self-defense system that recognizes and destroys 
external DNA and RNA, thereby leading to acquired immunity against invading plasmids and 
viruses (Horvath et al., 2010; Al-Attar et al., 2011). The CRISPR/Cas system is divided into three 
types based on the classification system proposed by Makarova and colleagues (2011). The type 
II CRISPR/Cas9 system is best characterized and belongs to the adaptive immune system of inter 
alia Staphylococcus pyogenes (Sp). It consists of the SpCas9 (hereafter referred to as Cas9) 
nuclease and the non-coding RNAs CRISPR RNA (crRNA) and trans-activating RNA (tracrRNA). 
While the crRNA recognizes and binds to the target sequence, the tracrRNA interacts with the 
crRNA to guide the Cas9 protein to the target site, allowing for target-specific cleavage 
(Chylinski et al., 2014)(Fig. 2). Binding is directed by protospacer-adjacent motifs (PAMs) which 
vary between CRISPR/Cas systems (Mojica et al., 2009): Cas9 recognizes the bases ‘NGG’ where 
N refers to any nucleotide and cleaves 3 basepairs (bp) upstream of the PAM (Jinek et al., 2012; 
Ran et al., 2013b). This PAM sequence in the human genome is found every 8-12 bp, providing 
 
FIG. 2 | Components of CRISPR/Cas9 complex. CRISPR-RNA (crRNA) complementary to the target sequence 
together with a bound scaffolding trans-activating RNA (tracrRNA) directs Cas9 nuclease to the target site. The 
complex recognizes the protospacer-adjacent motif (PAM) sequence and cleaves DNA 3 basepairs upstream of the 
PAM, most frequently inducing a double-strand break. crRNA: CRISPR-RNA; tracrRNA: trans-activating RNA; PAM: 
protospacer-adjacent motif.  
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an accessible and global target for Cas9 (Ran et al., 2013b).  CRISPR/Cas9-mediated genome 
editing editing outplays previous genome editing techniques in terms of efficacy, simplicity and 
(Ran et al., 2013b). CRISPR/Cas9-mediated genome editing outplays previous genome editing 
techniques in terms of efficacy, simplicity and multiplexing possibility. It involves designing 
crRNAs specific for the target site, transferring crRNAs, tracrRNAs and Cas9 to the cell and 
thereby inducing a site-specific double-strand break (DSB) that will be repaired by the host DNA 
repair system, leading to non-homologous end-joining (NHEJ) in most cases and homology-
directed repair (HDR) on rare occasions. If NHEJ occurs, it frequently leads to arbitrary 
insertions or deletions (indels), usually shifting the open reading frame and thus resulting in a 
premature stop codon (Hefferin et al., 2005). This repair mechanism is therefore of high interest 
for targeted gene disruption and generation of loss-of-function phenotypes. HDR events are rare 
but highly desired as the repair mechanism uses the homologous allele or an exogenous template 
like administered single-stranded oligodeoxynucleotides (ssODNs) to repair DSBs, allowing 
both single nucleotide changes and integration of whole exogenous sequences (van den Bosch 
et al., 2002; Chen et al., 2011; Ran et al., 2013b).   
Many protocols with slight modifications to enhance efficiency, stability and safety were 
published since the first discovery: efficiency and stability was improved by replacing the 
tracrRNA:crRNA duplex with a stable single guide RNA (sgRNA)(Jinek et al., 2012); a nuclear 
localization sequence was integrated into Cas9 to enhance nuclear translocation (Cong et al., 
2013; Mali et al., 2013); Cas9 nickases with mutations in specific domains were developed to only 
cleave one DNA strand (Ran et al., 2013a; Murovec et al., 2017); different delivery methods of 
sgRNA and Cas9 have been applied, ranging from plasmids, mRNA and protein to 
ribonucleoprotein (RNP) complexes; and the delivery of the complexes varied between 
electroporation, transfection or transduction (Liang et al., 2015). Furthermore, a tracrRNA 
tagged with the fluorophore ATTO550 now allows for selection of cells with incorporated RNP 
complexes by fluorescence-activated cell sorting.   
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The major drawback of CRISPR/Cas9-mediated genome editing still remains the off-target 
effects, albeit occurring at a very low frequency only. Although cleavage at the target site is based 
on the complementarity of approximately 20 bp of the crRNA and the target sequence, a partial 
complementarity with mismatch pairings may lead to DNA cleavage at off-target sites. Several 
bioinformatical tools that are used for designing crRNAs predict possible off-target effects and 
calculate the likelihood of this cleavage based on the number, the position and the distribution 
of mismatches (Hsu et al., 2013). SpCas9, for example, tolerates up to six mismatches at target 
sites (out of 18-24 nucleotides)(Jinek et al., 2012).  
Off-target cleavage is reduced by the delivery of RNP complexes (Kim et al., 2014b; Liang et al., 
2015), by an inducible and therefore temporarily restricted expression of Cas9 (Cao et al., 2016), 
a titrated dosage of Cas9 and sgRNA (Hsu et al., 2013; Liang et al., 2015) and most notably by 
Cas9 nickases (Ran et al., 2013a; Cho et al., 2014; Iyer et al., 2015; Murovec et al., 2017). Although 
the reduction in off-target frequency is sufficient for many in vitro disease models, it still renders 
in vivo applications for permanent gene correction in patients difficult. 
For disease modeling, as mentioned above, an efficient method for gene is often desired. Chen 
and colleagues (2014) optimized the generation of knockouts by applying two sgRNAs for one 
gene for dual cleavage of the DNA and deletion of the DNA fragment in between the two 
cleavage sites. This has one major advantage: the successful cleavage can easily be detected and 
screened for with PCR product amplification and agarose gel electrophoresis. 
For proper disease modeling of SCAR16, we generated a homozygous knockout of STUB1 by 
designing two crRNAs for exon 2 and 3 followed by the formation of two crRNA-ATTO550-
tracrRNA complexes and the formation of a ribonucleoprotein complex by adding Cas9 protein 
(see workflow in Fig. 3). We then harvested iPSCs and nucleofected them followed by 
fluorescence-activated cell sorting of ATTO550-positive cells, single cell seeding and manual 
picking of colonies. DNA of those clones was isolated, amplified by PCR, tested on gel 
electrophoresis and verified by Sanger sequencing for homozygous and heterozygous clones.  
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FIG. 3 | Schematic workflow for CRISPR/Cas9-dual cleavage gene knockout. (1) Two distinct single guide (sg) 
RNAs are generated by the formation of a complex of target-specific CRISPR-RNA (crRNA) and an ATTO550-labelled 
trans-activating RNA (tracrRNA). (2) Cas9 binds to the sgRNA, forming a ribonucleoprotein (RNP) complex. (3) The 
cells to be edited, iPSCs, are harvested and (4) electroporated with the RNP complex. RNP complexes bind to target 
sequences and cleave DNA 3 bp upstream of the protospacer-adjacent motif (PAM). (5) After incubation, cells are 
sorted by fluorescence-activated cell sorting and cells positive for ATTO550 are seeded as single cells. (6) After 
approximately 7 days, colonies are picked manually, DNA is isolated and amplified by PCR and clones are tested with 
agarose gel electrophoresis for dual cleavage. (7) Selected clones are sequenced by Sanger sequencing to confirm the 
homozygous or heterozygous knockout. RNP: ribonucleoprotein; iPSC: induced pluripotent stem cells; WT: wildtype; 
KO: knockout.  
 
Top 5 off-target effects per crRNA as predicted by CRISPOR (Haeussler et al., 2016) were 
excluded by Sanger sequencing, and generated iPSCs were characterized based on genomic 
integrity and pluripotency (Schuster et al., 2019, Fig. 1). Combining the iPSC technology with 
CRISPR/Cas9-mediated genome editing to create an isogenic knockout and the differentiation 
into the proper cell type that is affected by the disease allows for ideal disease modeling of 
monogenic neurological disorders such as SCAR16. 
5. Carboxy-terminus of the heat shock cognate 70 interacting protein 
The gene ‘STIP1 homology and U-box containing protein 1’ (STUB1) codes for the protein ‘C-
terminus of the heat shock cognate 70 interacting protein’ (CHIP). Mutations in STUB1 cause 
early-onset autosomal recessive cerebellar ataxia type 16 (SCAR16, OMIM 615768), a movement 
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disorder characterized by atrophy of the cerebellum, brain stem and spinal cord. Symptoms 
range from loss of muscle coordination, unsteady gait, impaired fine motor skills and a slurry 
speech to epilepsy, hypogonadism and cognitive impairment (Shi et al., 2013; Heimdal et al., 
2014; Shi et al., 2014; Synofzik et al., 2014; Bettencourt et al., 2015; Hayer et al., 2017), indicating a 
broad neurodegeneration. 19 pathogenic variants as summarized by the Human Gene Mutation 
Database (www.hgmd.cf.ac.uk) were described as of yet.   
CHIP plays a crucial role in protein quality control and maintenance of cellular homeostasis. 
Acting as an asymmetric homodimer (Zhang et al., 2005), it can bind to the C-termini of 
chaperones like HSC70/HSP70 and HSP90 modulating their activity via its tetratricopeptide 
repeat (TPR) domain (Ballinger et al., 1999). Via its U-box domain, it tags chaperone-bound and 
other substrates with ubiquitin through its E3 ligase activity (Jiang et al., 2001; Murata et al., 
2003). This dual role of CHIP of both molecular co-chaperone and E3 ubiquitin ligase is 
exceptional. CHIP enables poly-ubiquitination with both Lysin-48- and Lysin-63-linked chains, 
leading to the degradation via the ubiquitin-proteasome system and the autophagy-lysosome 
system, respectively (Zhang et al., 2005; Yao, 2010; Guo et al., 2015). More recently, CHIP was 
identified as a regulator of many other important cellular processes like cAMP/AMPK signaling 
(Schisler et al., 2013; Rinaldi et al., 2019), chaperone-mediated autophagy (Ferreira et al., 2015), 
necroptosis (Seo et al., 2016; Tang et al., 2018), oxidative metabolism (Ravi et al., 2018) and the 
regulation of TFEB activity and thereby regulation of macroautophagy (Guo et al., 2015; Sha et 
al., 2017).  
Further highlighting the importance of CHIP, it was shown to be cytoprotective in many 
neurodegenerative diseases by degrading i.a. α-synuclein (Shin et al., 2005; Tetzlaff et al., 2008), 
LRRK2 (Ding et al., 2009), APP and BACE1 (Kumar et al., 2007; Singh et al., 2015) and huntingtin 
(Jana et al., 2005; Miller et al., 2005). This leads to the assumption that CHIP may be a key player 
of neurodegeneration and a promising target for the treatment of many neurodegenerative 
diseases. Strengthening the aforementioned role of CHIP in neurodegeneration, CHIP 
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overexpression caused attenuated tau aggregation in vivo (Sahara et al., 2005), decreased Aß 
levels and stabilized APP levels in vivo (Kumar et al., 2007) and reduced α-synuclein-associated 
inclusion bodies in vitro (Shin et al., 2005).  
CHIP is strongly expressed in heart, skeletal muscle and brain; all are tissues with high metabolic 
activity (Ballinger et al., 1999). In rodent brains, CHIP expression is strongest in neurons of the 
cerebellum, pons, medulla oblongata, hippocampus and cerebral cortex (Sahara et al., 2005; 
Anderson et al., 2010). CHIP knockout in flies, worms and mice leads to reduced lifespan and an 
increased ageing phenotype (Min et al., 2008; Tawo et al., 2017). CHIP-/- mice are viable but 
display severe cerebellar atrophy specifically in the Purkinje cell layer, with a distinct motor and 
cognitive impairment phenotype and aging-induced cardiac hypertrophy (Min et al., 2008; Shi 
et al., 2014). They presented with decreased stress tolerance, increased oxidative damage and 
soluble aberrantly folded proteins that were rarely seen in their wildtype littermates (Dai et al., 
2003; Min et al., 2008; Shi et al., 2014). Most strikingly 20% of CHIP-/- offspring die postnatally 
and 100% of mice die upon thermal challenge (Dai et al., 2003), suggesting a key role of CHIP in 
stress response, and more specifically the heat shock response (HSR). 
6. Heat shock response 
 
The heat shock response is induced by environmental stressors such as heat, heavy metals and 
reactive oxygen species and pathophysiological stressors such as protein aggregation, 
inflammation and tissue injury. It is a cellular process that increases the number of heat shock 
proteins (HSPs) rapidly upon stress induction, to prevent and reverse protein misfolding and to 
reestablish cellular homeostasis (reviewed by Richter et al., 2010). This increase of heat shock 
proteins is regulated by its key transcription factor heat shock factor 1 (HSF1). Under basal 
conditions, HSF1 is present in the cytosol in its’ inactive monomeric state, bound to 
HSC70/HSP70 and HSP90 (Abravaya et al., 1991)(Fig. 4, left panel). Only few misfolded proteins 
are present that can usually be refolded by chaperones. Upon stress, misfolded proteins 
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accumulate, leading to recruitment of chaperones and dissociation of those HSPs from HSF1 
(Santoro, 2000)(Fig. 4, right panel). HSF1 quickly trimerizes and various post-translational 
modifications like phosphorylation, acetylation and SUMOylation occur, modulating its’ 
activity. Trimerized HSF1 with bound CHIP translocates to the nucleus (Baler et al., 1993; Sarge 
et al., 1993; Dai et al., 2003; Kim et al., 2005). It then binds to heat shock elements and induces 
the transcription of HSPs within less than 30 minutes, leading to the synthesis and an 
enrichment of HSPs within hours (Baler et al., 1993; Sarge et al., 1993). Stress inducibility is 
highest for chaperones of the HSP70 (encoded by inter alia HSPA1A, HSPA1B, HSPA1L, HSPA6) 
and the HSP40 family (DNAJB1, DNAJB2, DNAJB6), while the expression of many chaperones is 
not altered upon stress (reviewed by Hageman et al., 2009). HSPs can either facilitate refolding 
 
FIG. 4 | Heat shock response in unstressed and stressed cells. (Left panel) In unstressed cells, monomeric HSF1 
is shielded by heat shock proteins (HSPs) like HSC70 or HSP90 and the few misfolded proteins that are present get 
refolded by chaperones. (Right panel) Upon stressors like heat, oxidative stress, inflammation, protein aggregation or 
ageing, the amount of misfolded proteins increases. (1) This leads to recruitment of heat shock proteins and thereby 
release of HSF1 which (2) quickly trimerizes, undergoes post-translational modifications (e.g. phosphorylation) and 
(3) translocates to the nucleus together with bound CHIP. Trimeric HSF1 binds to heat shock elements and leads to 
(4) transcription of heat shock proteins, mainly of the HSP70 and HSP40 family. These proteins bind to misfolded 
and aggregated proteins and either lead to refolding or tagging with ubiquitin, where CHIP is involved. HSPs that did 
not bind misfolded proteins can be tagged with ubiquitin by CHIP and get degraded. CHIP: C-terminus of the heat 
shock cognate 70 interacting protein; HSF1: heat shock factor 1; HSPs: heat shock proteins; P: phosphorylation; Ub: 
ubiquitin.  
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of misfolded proteins or allow tagging of them with ubiquitin which leads to proteasomal or 
lysosomal degradation and consequently to cytoprotection (reviewed by Richter et al., 2010). 
Other small HSPs (sHSPs) like HSPB1, HSPB5 and HSPB8 assist chaperones by binding to 
unfolded proteins to prevent further aggregation (Acunzo et al., 2012). Once the HSP levels 
exceed the need and the cellular homeostasis is re-established, ‘naked’ HSPs inhibit HSF1 again 
by binding to it, providing a negative feedback loop for HSR induction and their own 
transcription (Abravaya et al., 1991; Baler et al., 1992; Vjestica et al., 2013). Furthermore, CHIP 
can tag excess HSPs with ubiquitin, leading to their degradation (Qian et al., 2006). The detailed 
role of CHIP in the HSR will be discussed in the next chapter. 
Proteotoxic stress is considered among the most common causes of neurodegenerative diseases. 
In many cases such as AD, PD, HD and ALS, proteotoxic stress has directly been linked to 
compromised HSR in vitro and/or in vivo (reviewed by San Gil et al., 2017). Neurons are 
considered to be more vulnerable to stress and homeostatic disturbances in protein quality 
control as a consequence of their postmitotic state that prevents dilution of misfolded and 
aggregated proteins by cell division. This highlights the significance of chaperones in 
neuroprotection, and the need of careful selection of appropriate disease cell types.   
6.1 Modeling the HSR in SCAR16 patient-derived fibroblasts and 
cortical neurons 
CHIP not only mediates essential protein triage decisions to maintain cellular homeostasis, it is 
also involved in HSR activation and recovery: CHIP and HSF1 directly interact upon stress 
stimuli, leading to subsequent increased HSP70 expression in COS7 and HEK293T cells and 
CHIP overexpression increased HSF1 activation (Dai et al., 2003; Kim et al., 2005; Qian et al., 
2006). The interaction is dependent on a functional TPR domain, as mutant K30A CHIP – HSF1 
interaction was abolished (Dai et al., 2003). In addition to that, CHIP also plays a role in HSR 
recovery by ubiquitin tagging of excess HSP70, leading to its degradation. This is dependent on 
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both a functional TPR and U-box domain. The affinity of CHIP is higher for HSP70 and other 
HSPs with bound misfolded proteins than for ‘naked’ HSPs, ensuring a depletion of misfolded 
proteins before HSPs will be tagged with ubiquitin and degraded. Furthermore, CHIP’s affinity 
for HSP70 is higher than for HSC70 (Qian et al., 2006). 
As mentioned previously, 100% of CHIP-/- mice die upon thermal challenge at 42°C for 15 min 
and HSP70 expression upon heat shock in CHIP-/- mice is strongly reduced in most tissues, with 
almost absent levels in brain, heart and spleen (Dai et al., 2003).  
It needs to be highlighted that all experiments in vitro up to now were performed in cells of 
mesodermal origin, which are of questionable relevance for disease modeling as CHIP mutations 
in humans lead to a neurodegenerative phenotype. We therefore analyzed the effect of STUB1 
mutations on HSR in patient-derived cells in vitro, in both fibroblasts and neurons as the disease-
relevant cell type.  
By analyzing patient- and control-derived fibroblasts from skin biopsies, we were able to 
replicate previous findings from cell lines that indicate an impaired HSR induction on transcript 
and impaired HSR recovery on protein level, with remaining higher HSP70 expression in patient-
derived cells (Schuster et al., in preparation, Fig. 2). This suggests either an impaired 
ubiquitination of HSP70 by CHIP and less degradation or higher misfolded protein levels and 
therefore a higher need for more HSP70, or a combination of both. 
In contrast to the observations in our patient-derived fibroblasts, we could not detect an 
impaired HSR induction or recovery in cortical neurons of STUB1 patients. Although we did not 
see a difference in HSF1 levels in the nucleus upon heat shock, we saw an even higher HSPA1A/B 
and DNAJB1 transcript level in patients’ neurons compared to controls. On protein level, though, 
almost no change in HSP70 levels upon heat shock or recovery can be seen, without any 
difference between control and patient cells (Schuster et al., in preparation, Fig. 5). The 
difference in the observation in neurons and fibroblasts may have several reasons: 1) an impaired 
HSR in the brain might be relevant and disease-causing but not in neurons (astrocytes show a 
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stronger HSR in vivo and might be the more relevant cell type; or specific cell types like Purkinje 
cells might show higher HSR induction), 2) alterations of the HSR that were seen in patient-
derived fibroblasts but not in cortical neurons are not disease-relevant, as the diseased cell type 
does not show any changes, or 3) the low HSR is an in vitro artifact as the basal HSP70 level is 
already very high and this might not represent the cellular complexity of the in vivo situation. 
High basal HSP70 levels might by caused by neuronal monocultures, by cell culture conditions 
(like media composition or 2D monolayer structure) or by the embryonic age of iPSC-derived 
neurons, as e.g. HSPA1A expression is highest in fetal tissue (Hageman et al., 2009). Persistently 
high levels of HSP70 are detrimental to cells (Feder et al., 1992; Volloch et al., 1999) so additional 
induction of HSP70 upon stress might be prevented in iPSC-derived cortical neurons.   
Interestingly, comparing the cell viability of fibroblasts and CNs upon prolonged heat stress, we 
observed a higher stress vulnerability and toxicity in fibroblasts compared to neurons: while only 
30% of fibroblasts were viable after 4h at 42.5°C, still >95% of neurons were viable, yet in both 
cases independent of functional CHIP (Schuster et al., in preparation, Fig. 1, 4). A lower HSR 
induction in neurons might be linked to the higher resistance to this stress stimulus.  
6.2 Comparing the HSR in different cell types and tissues 
Although the genetic code is identical throughout all cells of the body, the transcript and protein 
expression varies greatly. While the HSR is evolutionarily well conserved across species, the 
tissue and cell variability of the expression of heat shock proteins varies greatly in humans: 
Hageman and Kampinga (2009) analyzed human expression data from 45 different tissues and 
7 developmental stages (ranging from embryoid blast to adult) from the NCBI UniGene 
database. They observed strong tissue specificity of most HSPH (HSP100 family), HSPA (HSP70 
family) and DNAJ (HSP40 family) isoforms, but the expression of HSPA1A is the most variable 
across tissues and developmental stages. Focusing on analyses of the brain, heat shock in rodents 
in vivo led to strongest HSP70 induction in the dentate gyrus, hypothalamus and the cerebellum 
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(Blake et al., 1990; Li et al., 1992). Other HSPs like DNAJB2A (HSP70 family) and HSJ1a/b (HSP40 
family) are highly enriched in neuronal tissue in general (Cheetham et al., 1992; Chapple et al., 
2003). In vitro analyses that compared heat shocked glial cells to heat shocked neurons revealed 
a higher induction of HSP70 in glial cells (Nishimura et al., 1991; Marcuccilli et al., 1996; Vogel et 
al., 1997; Batulan et al., 2003). Causes for the lower HSP70 induction in neurons are still a matter 
of debate. Some claim that differentially expressed co-chaperone levels might be the cause, with 
the basal expression level of the CHIP- and thereby HSR-inhibiting co-chaperone HSPBP1 being 
higher in neurons compared to glial cells (Zhao et al., 2017) while the basal expression level of 
HSPB1/HSP27 is inverted. However, levels of HSP27 were shown to increase in neurons upon 
heat shock, while they do not change in astrocytes (Satoh et al., 1995). Differences can also be 
caused by post-translational modifications of the HSP70 promoter, as acetylation upon heat 
shock is lower in cortical neurons compared to PC12 cells (Gomez et al., 2015), making it less 
accessible for HSF1 binding.  
We detected a specificity of HSPB1 and HSPB8 induction on transcript level upon heat shock for 
neurons compared to fibroblasts, although basal levels of both were higher in fibroblasts 
compared to neurons, indicating an important role of both small HSPs in stress coping in 
neurons. Vice versa we could detect a stronger HSPA1A/B induction upon heat shock in 
fibroblasts compared to neurons (Schuster et al., in preparation, Fig. 2,5).  
7. STUB1-mutant effects independent of the HSR 
CHIP plays a key role in protein quality control via its two functional domains, the TPR domain 
and the U-box domain. Mutations in STUB1 that were linked to SCAR16 were previously shown 
to lead to a destabilized structure of CHIP (Pakdaman et al., 2017; Kanack et al., 2018; Shi et al., 
2018). Other mutations were reported to impair CHIP’s ability to ubiquitinate its substrates 
(Heimdal et al., 2014; Ronnebaum et al., 2014; Pakdaman et al., 2017; Kanack et al., 2018; Shi et 
al., 2018; Madrigal et al., 2019).   
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Gene ontology (GO) enrichment analysis of proteomic data of cortical neurons of 3 healthy 
controls and 3 STUB1 patients revealed the absence of some protein folding and ubiquitin 
system-related proteins in patient-derived cortical neurons. Contrarily, GO terms of oxidative 
stress coping were enriched in patients only (Schuster et al., in preparation, Fig. 6). The 
relevance of specific substrate ubiquitination is yet unknown, as the human genome codes for 
more than 600 E3 ligases that have overlapping substrates. Morishima and colleagues (2008) 
reported a redundancy of the E3 ligases Parkin and CHIP for many substrates like nitric oxide 
synthase (NOS), the glucocorticoid receptor (GR) and expanded glutamine androgen receptor. 
This highlights the importance of identifying selective and unique substrates of CHIP which 
might cause proteotoxicity upon accumulation and subsequent cell death.  
8. Conclusion & Outlook  
Within the scope of this thesis, we generated induced pluripotent stem cells from patients with 
SCAR16 and a STUB1-CRISPR/Cas9-mediated homozygous knockout and differentiated all iPSC 
lines into cortical neurons. We tried to elucidate the effect of CHIP mutations on the HSR in 
cortical neurons but did not observe a substantial difference between patient and control lines 
and a very weak induction of HSP70 on protein level in all cell lines. However, the impairment 
of the HSR by dysfunctional CHIP as described previously was observed in patient-derived 
fibroblasts compared to healthy controls. As discussed earlier, the difference between 
dysregulated HSR by CHIP mutations in fibroblasts and cortical neurons might have several 
reasons: 1) disturbances in the HSR are not disease-relevant, 2) dysfunctional HSR in cortical 
neurons might not be causative for the disease but another cell type of the brain e.g. astrocytes 
that were described to have a higher HSR induction compared to neurons might trigger the 
dysfunction of neurons, or 3) the weak HSR induction and the high basal HSP70 level might be 
an in vitro artifact of e.g. the monoculture and might not represent the cellular complexity of 
the in vivo situation.   
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The data of this doctoral thesis highlights the importance of careful selection of disease models. 
iPSCs allow for disease modeling in cells with patient-specific genetic backgrounds and 
endogenous protein levels; however, we did not observe a dysregulation in iPSC-derived cortical 
neurons that we could detect in patient-derived fibroblasts.  
Considering the possible causes of this difference, changing the cell type might be of interest. 
As astrocytes in vivo show a stronger HSR, the same experimental setup for heat shock response 
analysis should be tested in iPSC-derived astrocytes. Furthermore, recent advances in 3D 
organoids that are generated in vitro but mimic the in vivo architecture of the organ with 
multiple cell types hold promise for modeling neurodegenerative diseases, but they bear the 
disadvantages of long cultivation, cell death in the organoids’ cores caused by low nutrient and 
gas exchange as well as high variability between experiments and lines (reviewed by Grenier et 
al., 2019). So far, only one protocol for cerebellar organoids from hESCs was published 
(Muguruma et al., 2015), but generation was not replicated for iPSCs.  
It would also be of high interest to analyze cell type-specific responses in CHIP-/- mice which 
might elucidate the role of neurons and astrocytes in stress coping and a potential dysregulation 
caused by dysfunctional CHIP.   
Overcoming the existing challenges of finding the right in vitro disease model might help to 
elucidate key pathological events of SCAR16 and help to improve therapeutic approaches for 
patients. Given the importance of CHIP in central protein triage decisions, understanding the 
pathophysiology of SCAR16 and modifying CHIP levels can help to mitigate other 
neurodegenerative diseases as well.   
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STUB1/CHIP is a central component of cellular protein homeostasis and interacts with key proteins involved in
the pathogenesis of many neurodegenerative diseases. Here, we reprogrammed human skin fibroblasts from a
12-year-old male patient with recessive spinocerebellar ataxia type 16 (OMIM #615768), carrying compound
heterozygousmutations (c.355CNT, c.880ANT) in STUB1.Genomic integrity of the iPSC lineHIHCNi001-Awithout
transgene integration and genomic aberration but with maintained disease-relevant mutations was proven by
SNP array analysis and Sanger sequencing while pluripotency was verified by the expression of important
pluripotency markers and the capacity to differentiate into cells of all three germ layers.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Resource table. Resource utility
CHIP is a central component of cellular protein homeostasis and in-
teracts with several key proteins associated with neurodegenerative
diseases, with mutations in STUB1 leading to SCAR16 (Hayer et al.,
2017; Synofzik et al., 2014). iPSC-derived neurons will help to further
decipher the exact role of this neurodegenerative key protein, including
central steps in the pathogenesis of SCAR16.
Resource details
HIHCNi001-Awas generated by reprogramming fibroblasts cultured
from a skin biopsy of a 12 year old boy suffering from autosomal reces-
sive spinocerebellar ataxia type 16 (SCAR16). SCAR16 patients develop
a severe early-onset multi-systemic neurodegenerative disorder
resulting in a broad phenotypic spectrum, including cerebellar ataxia,
spasticity, epilepsy and hypogonadism.While it is of high interest to de-
termine the pathophysiological role of CHIP, the protein encoded by
STUB1, it is also a promising possible key player of neurodegeneration
as it interacts with inter alia α-Synuclein, LRRK2, Huntingtin, Ataxin-3
and Tau. Our patient carried two heterozygous mutations c.355C NT
and c.880A NT in the STUB1 gene leading to a premature stop p.
Arg119* and an amino acid exchange p.Ile294Phe on the protein level.
Compound heterozygosity of the mutations was shown by segregation
analysis (Hayer et al., 2017). Fibroblasts were reprogrammedby the de-
livery of episomal plasmids encoding human OCT4, SOX2, KLF4, L-MYC
(OSKM) and LIN28 (Okita et al., 2011). iPSCs exhibited a morphology
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Unique stem cell line identifier HIHCNi001-A
Alternative name(s) of stem cell line iPSC-STUB1
Institution Hertie Institute for Clinical Brain
Research and German Center for
Neurodegenerative Diseases (DZNE),
University of Tübingen, Germany
Contact information of distributor Stefan Hauser, Stefan.hauser@dzne.de
Type of cell line Induced pluripotent stem cell (iPSC)
Origin Human
Additional origin info 12 years, male
Cell Source Fibroblasts
Clonality clonal
Method of reprogramming Non-integrating episomal plasmids
Genetic Modification NO
Type of Modification N/A
Associated disease Spinocerebellar ataxia, autosomal
recessive 16 (SCAR16), OMIM #615768
Gene/locus STUB1, c.[355CNT]; c.[880ANT]
Method of modification N/A
Name of transgene or resistance N/A
Inducible/constitutive system N/A
Date archived/stock date December 2016
Cell line repository/bank N/A
Ethical approval Institutional Review Board of the
Medical Faculty, University of Tübingen
Approval Number: 598/2011BO1
https://doi.org/10.1016/j.scr.2018.04.001
1873-5061/© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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similar to those of human embryonic stem cells andwere assessed after
manual picking and expansion for several passages. Cells expressed
pluripotency-associated surface markers such as alkaline phosphatase
(Fig. 1D) and did not express exogenous reprogramming factors after
passage 5 (Fig. 1C). Endogenous expression of pluripotency genes
OCT4 and TRA1-81 on protein level was verified by immunocytochem-
istry (Fig. 1E). OCT4, NANOG, KLF4, c-MYC, SOX2, REX1, DNMT3B and
TDGF1 were further verified on transcript level via qRT-PCR to have a
Fig. 1. Characterization and validation of HIHCNi001-A.
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similar expression compared to the human embryonic stem cell line
HUES 6 and a discriminative expression pattern compared tofibroblasts
(Fig. 1G). Pluripotency was further demonstrated by embryoid-body-
based differentiation to endodermal, mesodermal and ectodermal cell
lineage (Fig. 1F). Genomic integrity was confirmed by SNP genotyping
(Fig. 1A) and Sanger sequencing of the mutation site (Fig. 1B) of both
original fibroblasts and generated iPSCs. The cell line was confirmed to
be mycoplasma-free (Suppl. Fig. 1).
Materials and methods
Culturing and reprogramming fibroblasts
Human dermal fibroblasts were cultured in fibroblast culture me-
dium [DMEMhigh glucose (Life Technologies)+ 10% FBS (Life Technol-
ogies)] for 10 days at 37 °C, 5% CO2. Reprogramming was achieved by
nucleofection with the episomal plasmids pCXLE-hUL, pCXLE-hSK and
pCXLE-hOCT4 as described by Okita et al. Briefly, 105 cells were
nucleofected with 1 μg of each plasmid. After electroporation, fibro-
blasts were cultivated in fibroblast medium before adding FGF2
(2 ng/ml (Peprotech)) on day 2. The following day, medium was
changed to Essential 8 (E8) mediumwith 100 μMNaB (Sigma-Aldrich).
After 3–4 weeks with medium change every other day, colonies were
picked and expanded on matrigel-coated plates in E8 medium. After
≥5 passages, iPSCs were genomically and functionally analysed, pas-
saged or frozen in E8 medium with 40% KO-SR (Life Technologies),
10% DMSO (Sigma-Aldrich) and 1 μM Y-27632 (Abcam Biochemicals)
(Table 1).
Genomic integrity analysis
To verify genomic integrity, DNA of iPSCs and fibroblasts was iso-
lated with DNeasy Blood & Tissue Kit (Qiagen) according to the manu-
facturer's instructions. Whole-genome SNP genotyping was conducted
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Not shown, available
with author
Phenotype Qualitative analysis Immunocytochemistry of pluripotency markers:
OCT4, TRA1-81
Fig. 1 panel E
Quantitative analysis qRT-PCR for OCT4, NANOG, KLF4, c-MYC, SOX2,
REX1, DNMT3B and TDGF1
Fig. 1 panel G
Genotype/identity Whole genome SNP genotyping with Infinium
OmniExpressExome-8 BeadChip (Illumina) Spacing
(kb): Mean: 3,03, Median: 1,36
No larger chromosomal aberrations or copy
number variations; Genotype 46, XY
Fig. 1 panel A
Mutation analysis Sequencing Compound heterozygous, c.355CNT and c.880ANT Fig. 1 panel B
Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR, negative Supplementary file 1
Differentiation potential Embryoid body formation Smooth muscle actin (SMA), β-tubulin (TUJ) and
FOXA2, SOX17
Fig. 1 panel F
Donor screening HIV 1 + 2 Hepatitis B, Hepatitis C N/A
Genotype additional info Blood group genotyping N/A
HLA tissue typing N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Goat anti-OCT4 1:100 Santa Cruz, AB_653551
Mouse anti-TRA1-81 1:500 Millipore, AB_177638
In vitro differentiation Mouse anti-SMA 1:100 Dako, AB_2223500
goat anti-SOX17 1:250 R&D Systems, AB_355060
rabbit anti-FOX-A2 1:300 Millipore, AB_390153
mouse anti-TUJ 1:1000 Sigma Aldrich, AB_477590
Secondary antibodies Alexa Fluor 488 Donkey anti-Goat IgG 1:300 Life Technologies
Alexa Fluor 488 Goat anti-Rabbit IgG 1:300 Life Technologies
Alexa Fluor 488 Goat anti-Mouse IgG 1:300 Life Technologies
Alexa Fluor 568 Goat anti-Mouse IgG 1:300 Life Technologies
Alexa Fluor 568 Goat anti-Rabbit igG 1:300 Life Technologies
Primers
Target Forward primer Reverse primer (5′–3′)
Episomal plasmids KLF4 CCACCTCGCCTTACACATGAAG TAGCGTAAAAGGAGCAACATAG
L-MYC GGCTGAGAAGAGGATGGCTAC T TTTGTTTGACAGGAGCGACAA
OCT3/4 CATTCAAACTGAGGTAAGGG TAGCGTAAAAGGAGCAACATAG
SOX2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAAT
Pluripotency markers (qPCR) c-MYC ATTCTCTGCTCTCCTCGACG CTGTGAGGAGGTTTGCTGTG
DNMT3B ACGACACAGAGGACACACAT AAGCCCTTGATCTTTCCCCA
KLF4 CCATCTTTCTCCACGTTCGC CGTTGAACTCCTCGGTCTCT
NANOG CAAAGGCAAACAACCCACTT TGCGTCACACCATTGCTATT
OCT4 GGAAGGTATTCAGCCAAACG CTCCAGGTTGCCTCTCACTC
SOX2 TGATGGAGACGGAGCTGAAG GCTTGCTGATCTCCGAGTTG
TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGC
Housekeeping gene (qPCR) GAPDH AGGTCGGAGTCAACGGATTT ATCTCGCTCCTGGAAGATGG
Targeted sequencing Mutation_1 GCTACCTGAAGATGCAGCAG TGAGCCTGGAGAGGTAAGAG
Mutation_2 GTGCAGTGCCCCTTTTCAG GTCCAACAGCAGAACTTGGG
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using Infinium OmniExpressExome-8-BeadChip (Illumina) and
GenomeStudio V2.0.3 (Illumina) for evaluation. Copy number analysis
was performed using CNVPartition plugin (Illumina). Early mosaicism
states were evaluated by manual review on B allele frequency plots on
chromosomal level. DNA was also sequenced for both mutations in
STUB1 using mutation-specific primers (Table 2) according to standard
procedures, using 3130xl Genetic Analyzer (Applied Biosystems) and
Staden 2.0.0b10 (Staden Sourceforge) for visualisation. To verify non-
integration of plasmids, RT-PCR was performed with plasmid-specific
primers (Table 2).
Pluripotency assessment
iPSCs were fixed with 4% paraformaldehyde (PFA) and either
assessed for alkaline phosphatase expression or permeabilized with
0.1% Triton X-100, blocked with 5% FBS and stained overnight at 4 °C
with primary antibodies for immunocytochemical analysis (Table 2).
Samples were visualized after staining with Alexa Fluor 488- or 568-
conjugated secondary antibodies (Table 2) for 1 h at room temperature.
Nuclei were counterstainedwithHoechst 33,342 (1:10.000, Invitrogen).
Samples were embedded in ProLong Gold Antifade Reagent (Life Tech-
nologies) and observed with AxioImager Z1 (Zeiss). On transcript level,
qRT-PCRwith primers specific for pluripotency genes (Table 2)was per-
formed: RNA was extracted with High Pure RNA Isolation Kit (Roche)
according to manufacturer's instructions and reverse-transcribed to
cDNA, using Transcriptor High Fidelity cDNA Synthesis Kit (Roche).
qRT-PCR was performed as triplicates with LightCycler 480 SYBR
Green I Master (Roche). Normalization of CT values for GAPDH and the
reference hESC line HUES6 was achieved by using the 2−∆∆Ct method.
Pluripotency was further confirmed by embryoid-body based
differentiation by cultivating iPSCs in EB medium (80% DMEM/F12
(Life Technologies), 20% KO-SR, 1× NEAA (Sigma-Aldrich), 1×
Penicillin-Streptomycin (Merck Millipore), 2 mM L-Glutamine (Gibco),
0.1 mM β-Mercaptoethanol (Merck)) on AggreWell 800 Plates
(StemCell Technologies)withmediumchange on day 2. Embroid bodies
were collected on day 4 and plated onto 0.1% gelatine- or matrigel-
coated plates, for endo- and mesodermal or ectodermal differentiation,
respectively. Cells were cultivated for 2–3 weeks with medium change
every other day and immunocytochemically stained for SMA, TUJ,
FOXA2 and SOX17 (Table 2).
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.scr.2018.04.001.
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A B S T R A C T
STUB1/CHIP is a central component of cellular protein homeostasis and interacts with key proteins involved in the pathogenesis of many neurodegenerative diseases.
Missense and truncating mutations in STUB1 lead to SCAR16. For ideal in vitro disease modelling with isogenic controls, we generated a CHIP knockout cell line from
a healthy control with no CHIP functionality, but remaining genomic integrity and verified pluripotency.
Resource table
Unique stem cell line i-
dentifier
HIHCNi004-A-1
Alternative name(s) of
stem cell line
iPSC-STUB1_KO
Institution Hertie Institute for Clinical Brain Research, University of
Tübingen, and German Center for Neurodegenerative
Diseases (DZNE), Germany
Contact information of
distributor
Stefanie Schuster
Stefanie.schuster@klinikum.uni-tuebingen.de
Ludger Schöls ludger.schoels@uni-tuebingen.de
Type of cell line iPSC
Origin Human
Additional origin info Female, 37 years
Cell Source Fibroblasts
Clonality Clonal
Method of reprogram-
ming
Non-integrating episomal plasmids
Genetic Modification YES
Type of Modification CRISPR/Cas9-mediated gene knockout
Associated disease Spinocerebellar ataxia, autosomal recessive 16 (SCAR16),
OMIM #615768
Gene/locus STUB1; c.283-438del, p.Val94Alafs*5 (homozygous)
Method of modification CRISPR/Cas9
Name of transgene or r-
esistance
N/A
Inducible/constitutive s-
ystem
N/A
Date archived/stock da-
te
September 2018
Cell line repository/ba-
nk
N/A
Ethical approval Institutional Review Board of the Medical Faculty,
University of Tübingen
Approval Number: 598/2011BO1
Resource utility
CHIP is a central component of cellular protein homeostasis and
interacts with several key proteins associated with neurodegenerative
diseases, with mutations in STUB1 leading to SCAR16. For ideal in vitro
disease modelling with isogenic controls, we generated a CHIP
knockout cell line with no CHIP functionality.
Resource details
A skin biopsy was obtained from a healthy 37-year old woman
(Control, CO) and cultured fibroblasts were reprogrammed by the de-
livery of episomal plasmids encoding human OCT4, SOX2, KLF4, L-MYC
and LIN28. iPSCs exhibited a morphology similar to those of human
embryonic stem cells (hESCs) and were assessed after manual picking
and expansion for several passages. iPSC-CO (HIHCNi004-A) were then
nucleofected with two crRNA-Atto550 tracrRNA RNP complexes tar-
geting exon 2 and 3 of STUB1, followed by fluorescence-activated cell
sorting (FACS) of Atto550+-cells, single cell seeding and manual
picking. Homozygous knock-out state was confirmed to be c.283-
438del, p.Val94Alafs*5 (Fig. 1B), leading to nonsense-mediated decay
and a loss of CHIP protein as shown by protein expression analysis
(Suppl. Fig. 1) (Table 1).
iPSC-STUB1_KO (HIHCNi004-A-1) was verified to be pluripotent by
the expression of pluripotency-associated surface markers such as
https://doi.org/10.1016/j.scr.2018.101378
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alkaline phosphatase (Fig. 1D), the absence of exogenous reprogram-
ming factors after passage 5 (Fig. 1C) and the expression of endogenous
pluripotency genes OCT4 and TRA1–81 on protein level as shown by
immunocytochemistry (Fig. 1E). OCT4, NANOG, KLF4, c-MYC, SOX2,
REX1, DNMT3B and TDGF1 were further transcriptionally expressed in
a similar pattern compared to the hESC line HUES-I3 and the original
iPSC line iPSC-CO (Fig. 1G). Pluripotency was furthermore demon-
strated by embryoid body-based differentiation to endodermal, meso-
dermal and ectodermal cell lineage (Fig. 1F). Genomic integrity was
confirmed by whole genome SNP genotyping (Fig. 1A). Top 5 off-target
Fig. 1. Characterization and validation of HIHCNi004-A-1.
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effects of Cas9 for both crRNAs were excluded by Sanger sequencing
(data not shown). The cell line was confirmed to be mycoplasma-free
(Suppl. Fig.3). STR analysis of 7 loci confirmed cell identity of fibro-
blasts, iPSC-CO and iPSC-STUB1_KO.
In summary, we have generated a human disease-specific homo-
zygous CHIP knockout iPSC line. This will serve, together with patient-
derived generated iPSCs (Schuster et al., 2018), as an ideal tool for in
vitro disease modelling and pathological study of SCAR16.
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal Supplementary file 2
Phenotype Qualitative analysis Immunocytochemistry of pluripotency markers OCT4 and TRA1–81; Fig. 1 panel E
Expression of alkaline phosphatase Fig. 1 panel D
Quantitative analysis qRT-PCR for OCT4, NANOG, KLF4, c-MYC, SOX2, REX1, DNMT3B and
TDGF1
Fig. 1 panel G
Genotype Whole genome SNP genotyping with
Infinium
No larger chromosomal aberrations or copy number variations upon
CRISPR/Cas9 mediated genome editing
Fig. 1 panel A
OmniExpressExome-8 BeadChip
(Illumina)
Spacing (kb): Mean: 3,03; Median: 1,36
Identity STR analysis 7 sites; F-CO, iPSC-CO and iPSC-STUB1_KO all matched Submitted in archive with
journal
Mutation analysis Sequencing c.283-438del p.Val94Alafs*5 Fig. 1 panel B
Southern Blot OR WGS N/A
Microbiology and virology Mycoplasma Mycoplasma testing by RT-PCR, negative Supplementary file 3
Differentiation potential Embryoid body formation Smooth muscle actin (SMA), β-tubulin (TUJ) and FOXA2, SOX17 Fig. 1 panel F
Donor screening HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
Table 2
Reagents details.
Antibodies used for immunocytochemistry and Western Blotting
Antibody Dilution Company Cat # and RRID
Pluripotency Markers Rabbit anti-OCT4 1:100 Proteintech, AB_2167545 Millipore, AB_177638
Mouse anti-TRA1–81 1:500
In vitro Differentiation Mouse anti-SMA 1:100 Dako, AB_2223500 R&D Systems, AB_355060
goat anti-SOX17 1:250
rabbit anti-FOX-A2 1:300 Millipore, AB_390153 Sigma Aldrich, AB_477590
mouse anti-TUJ 1:1000
Western Blotting Rabbit anti-CHIP 1:10.000 Abcam, AB_2751008 Meridian Life Science, AB_151542
Mouse anti-GAPDH 1:10.000
Secondary antibodies Alexa Fluor 488 Goat anti-Mouse IgG 1:1000 Life Technologies
Alexa Fluor 488 Goat anti-Rabbit IgG 1:1000 Life Technologies
Alexa Fluor 488 Donkey anti-Rabbit IgG 1:1000 Life Technologies
Alexa Fluor 568 Donkey anti-Goat IgG 1:1000 Life Technologies
Peroxidase-conjugated AffiniPure goat anti mouse 1:10.000 Jackson ImmunoResearch
Peroxidase-conjugated AffiniPure goat anti-rabbit 1:10.000 Jackson ImmunoResearch
Primers
Target Forward primer Reverse primer (5′-3′)
Episomal Plasmids KLF4 CCACCTCGCCTTACACATGAAG TAGCGTAAAAGGAGCAACATAG
L-MYC GGCTGAGAAGAGGATGGCTAC TTTGTTTGACAGGAGCGACAAT
OCT3/4 CATTCAAACTGAGGTAAGGG TAGCGTAAAAGGAGCAACATAG
SOX2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAAT
Pluripotency Markers (qPCR) c-MYC GACTCTGAGGAGGAACAAGA TGATCCAGACTCTGACCTTT
DNMT3B GAGTATCAGGATGGGAAGGA ATAGCCTGTCGCTTGGA
KLF4 CCATCTTTCTCCACGTTCGC CGTTGAACTCCTCGGTCTCT
NANOG CAAAGGCAAACAACCCACTT TGCGTCACACCATTGCTATT
OCT4 GGAAGGTATTCAGCCAAACG CTCCAGGTTGCCTCTCACTC
SOX2 TGATGGAGACGGAGCTGAAG GCTTGCTGATCTCCGAGTTG
TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGC
Housekeeping Gene (qPCR) GAPDH AGGTCGGAGTCAACGGATTT ATCTCGCTCCTGGAAGATGG
Targeted sequencing of CHIP KO CHIP TGATTCTAGCCAGAGCGCAG TCGGGAGTCGGTGATTCAGA
CRISPR Guide RNAs
Target Sequence PAM Sequence
crRNAs CHIP exon 2 GCTGGACGGGCAGTCTGTGA AGG
CHIP exon 3 GAATCGCGAAGAAGAAGCGC TGG
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Materials and methods
Fibroblast reprogramming
For reprogramming, 105 human dermal fibroblasts were nucleo-
fected with 1 μg of each episomal plasmid pCXLE-hUL, pCXLE-hSK and
pCXLE-hOCT4, as described by Okita et al., 2011 After electroporation,
fibroblasts were cultivated in fibroblast medium [DMEM high glucose
+10% FBS (Life Technologies)] before adding FGF2 (2 ng/ml (Pepro-
tech)) on day 2. The following day, medium was changed to Essential 8
(E8) medium with 100 μM NaB (Sigma-Aldrich). After 3–4 weeks with
medium change every other day, colonies were picked and expanded on
matrigel-coated plates in E8 medium. iPSCs were frozen in E8 medium
with 40% KO-SR (Life Technologies), 10% DMSO (Sigma-Aldrich) and
1 μM Y-27632 (Abcam Biochemicals).
CRISPR/Cas9-mediated gene knockout
For STUB1/CHIP knockout, 6× 105 iPSC-CO cells of passage 14
were nucleofected with two crRNA-Atto550 tracrRNA RNP complexes
(Table 2) (Integrated DNA Technologies) in Amaxa Nucleofection So-
lution (Lonza) with supplement, followed by FACS of Atto550+-iPSCs,
single-cell seeding and picking after 5–8 days. Homozygous knockout
state was confirmed by PCR analysis of DNA and Sanger sequencing
using knockout-specific primers (Table 2) according to standard pro-
cedures, using 3130xl Genetic Analyzer (Applied Biosystems) and
CRISP-ID (Dehairs et al., 2016) for visualisation. Top 5 off-target effects
were excluded for both crRNAs by Sanger sequencing (data not shown).
Genomic integrity analysis
To verify genomic integrity, DNA of iPSC-CO and iPSC-STUB1_KO
was isolated with DNeasy Blood & Tissue Kit (Qiagen) according to
manufacturer's instructions. Whole-genome SNP genotyping was con-
ducted using Infinium OmniExpressExome-8-BeadChip (Illumina) and
GenomeStudio V2.0.3 for evaluation. Copy number analysis was per-
formed using CNVPartition plugin (Illumina). Early mosaicism states
were evaluated by manual review on B-allele frequency plots on chro-
mosomal level. STR analysis of 7 loci confirmed cell identity. To verify
non-integration of plasmids, RT-PCR was performed with plasmid-
specific primers (Table 2).
Pluripotency assessment
iPSCs were fixed with 4% PFA and assessed for alkaline phosphatase
expression. For immunocytochemical analysis, fixed iPSCs were per-
meabilized and blocked, followed by overnight staining with primary
antibodies at 4 °C and staining with Alexa Fluor 488- or 568-conjugated
secondary antibodies (Table 2) for 1 h at room temperature. Nuclei
were counterstained with Hoechst 33342 (1:10.000, Invitrogen). Im-
munofluorescence was visualized with AxioImager Z1 (Zeiss).
On transcript level, qRT-PCR with pluripotency genes-specific pri-
mers (Table 2) was performed: RNA was extracted with High Pure RNA
Isolation Kit (Roche) according to manufacturer's instructions and re-
verse-transcribed to cDNA, using Transcriptor High Fidelity cDNA
Synthesis Kit (Roche). qRT-PCR was performed as triplicates with SYBR
Select Master Mix (Applied Biosystems). CT values were normalized to
GAPDH and the reference hESC line I3 with the 2-∆∆Ct method. Plur-
ipotency was further confirmed by embryoid body-based differentiation
by cultivating iPSCs in EB medium (80% DMEM/F12 (Life Technolo-
gies), 20% KO-SR, 1× NEAA (Sigma-Aldrich), 1× Penicillin-Strepto-
mycin (Merck Millipore), 2 mM L-Glutamine (Gibco), 0.1mM β-Mer-
captoethanol (Merck)) on AggreWell800 Plates (StemCell
Technologies) with medium change on day 2. Embryoid bodies were
collected (day 4) and plated onto 0.1% gelatine- or matrigel-coated
plates, for endo- and mesodermal or ectodermal differentiation, re-
spectively. Cells were cultivated for 2–3weeks and im-
munocytochemically stained for SMA, TUJ, FOXA2 and SOX17
(Table 2).
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ABSTRACT 
CHIP encoded by the gene STUB1 is a co-chaperone and E3 ligase that acts as a key regulator of 
cellular protein homeostasis. Mutations in STUB1 cause autosomal recessive spinocerebellar 
ataxia type 16 (SCAR16) with widespread neurodegeneration manifesting as spastic-ataxic gait 
disorder, dementia and epilepsy. CHIP-/- mice present display severe cerebellar atrophy, show 
high perinatal lethality and impaired heat stress tolerance. To decipher the pathomechanism 
underlying SCAR16 we investigated the heat shock response (HSR) in primary fibroblasts of 
SCAR16 patients. We found impaired HSR induction and recovery compared to healthy controls. 
HSPA1A/B transcript levels (coding for HSP70) were reduced upon heat shock but HSP70 
protein levels were higher upon recovery in patient compared to control fibroblasts. As SCAR16 
primarily affects the central nervous system we next investigated HSR in cortical neurons 
derived from iPSC lines of three patients with STUB1 mutations. We found SCAR16 cortical 
neurons to be surprisingly resistant to heat stress. Neurons of both SCAR16 patients and healthy 
controls expressed high basal levels of HSP70 compared to fibroblasts. While heat stress resulted 
in strong increases of transcript levels of many HSPs, this did not translate into higher HSP70 
protein levels upon heat shock independent of STUB1 mutations. In addition, the HSR was 
similar in neurons from a homozygous STUB1 knockout generated by CRISPR/Cas9-mediated 
genome editing from an isogenic healthy control line. Proteomic analysis of cortical neurons 
showed dysfunctional protein (re)folding and a higher basal oxidative stress level in patients. 
Our results question the role of impaired HSR in SCAR16 neuropathology and highlight the need 
for careful selection of proper cell types for modelling human diseases. 
INTRODUCTION  
Mutations in STUB1 (STIP1 homology and U-box containing protein 1) cause early-onset 
autosomal recessive cerebellar ataxia type 16 (OMIM 615768), a movement disorder that is 
characterized by atrophy of the cerebellum, brain stem and spinal cord, leading to loss of muscle 
coordination, unsteady gait, impaired fine motor skills and a slurry speech (Shi et al., 2013; 
Bettencourt et al., 2015). Recently, patients with STUB1 ataxia were shown to present a broader 
neurodegeneration with complex clinical phenotypes of cognitive impairment, epilepsy and 
hypogonadism in addition to spastic-ataxic movement disorder (Shi et al., 2013; Heimdal et al., 
2014; Shi et al., 2014; Synofzik et al., 2014; Hayer et al., 2017). 
STUB1 codes for the ‘C-terminus of HSC70-interacting protein’ (CHIP) which plays an important 
role in protein quality control. Its two major functions are linked to two distinct structural 
domains: Via its tetratricopeptide repeat (TPR) domain, CHIP acts as a co-chaperone of 
HSC70/HSP70 and HSP90 and inhibits ATPase and refolding activity (Ballinger et al., 1999). Via 
its U box domain, it acts as an E3 ligase tagging chaperone-bound but also other substrates with 
ubiquitin (Jiang et al., 2001; Murata et al., 2003). Degradation of those proteins or organelles 
occurs via the ubiquitin-proteasome system (UPS) or the autophagy-lysosome system (Zhang et 
al., 2005; Yao, 2010; Guo et al., 2015). Both mechanisms play a major role in protein quality 
control and sustain proper cellular homeostasis.   
More recently, CHIP was identified as regulator of many other processes like TFEB activity and 
thereby macroautophagy regulation (Guo et al., 2015; Sha et al., 2017), necroptosis (Seo et al., 
2016; Tang et al., 2018), cAMP and AMPK signaling (Schisler et al., 2013; Rinaldi et al., 2019), 
oxidative metabolism (Ravi et al., 2018), chaperone-mediated autophagy (Ferreira et al., 2015) 
and neuronal preconditioning (Lizama et al., 2018). In addition to this, CHIP was shown to be 
cytoprotective in many forms of neurodegeneration by degrading inter alia α-synuclein (Shin et 
al., 2005; Tetzlaff et al., 2008), LRRK2 (Ding et al., 2009), APP and BACE1 (Kumar et al., 2007; 
Singh et al., 2015) as well as huntingtin (Jana et al., 2005; Miller et al., 2005). This leads to the 
assumption that CHIP may be a key player of neurodegeneration and a promising target for the 
treatment of many neurodegenerative diseases. Furthermore, CHIP was previously linked to 
cardiac and muscular disorders and several different types of cancers (reviewed by Joshi et al., 
2016).  
CHIP expression is highest in tissues with high metabolic activity, i.e. heart, skeletal muscle and 
brain (Ballinger et al., 1999). In mouse brains, CHIP is expressed primarily in neurons of the 
cerebellum, pons, medulla oblongata, hippocampus and cerebral cortex (Sahara et al., 2005; 
Anderson et al., 2010). CHIP-/- mice display severe cerebellar atrophy specifically in the Purkinje 
cell layer, with a distinct motor impairment phenotype. Furthermore, CHIP knockout mice were 
shown to have decreased stress tolerance and increased age-related phenotypes leading to 
decreased lifespan and a gonadal dysfunction (Dai et al., 2003; Min et al., 2008; Shi et al., 2014). 
Upon thermal challenge, 100% of CHIP-/- mice die during heat shock or shortly after (Dai et al., 
2003), suggesting a key role of CHIP in stress response, and more specifically the heat shock 
response (HSR).   
Environmental stressors such as heat, heavy metals and reactive oxygen species, but also 
pathophysiological stressors such as protein aggregation, inflammation and tissue injury can 
induce HSR, which is characterized by the rapid increase of heat shock protein expression 
(reviewed by Richter et al., 2010). This induction of heat shock proteins is regulated by the key 
transcription factor heat shock factor 1 (HSF1). Under basal conditions, HSF1 is present in the 
cytoplasm in its inactive monomeric form, shielded by HSC70/HSP70 and HSP90 (Abravaya et 
al., 1991). Upon stress, the chaperones blocking HSF1 are recruited to the site of accumulating 
misfolded proteins, thereby releasing HSF1 (Santoro, 2000). HSF1 quickly trimerizes, undergoes 
post-translational modifications that modulate its activity and translocates to the nucleus (Sarge 
et al., 1993). Here it binds to heat shock responsive elements, leading to transcription of heat 
shock proteins such as HSPA1A/B (encoding HSP70) and DNAJB1 (encoding HSP40) that act to 
refold or clear misfolded proteins and confer cytoprotection (reviewed by Richter et al., 2010). 
Other small HSPs (sHSPs) like HSPB1, HSPB5 and HSPB8 assist by binding to unfolded proteins 
to prevent aggregation (Acunzo et al., 2012). Once cellular homeostasis is reestablished, free 
HSPs inhibit HSF1 and attenuate the HSR (Abravaya et al., 1991; Baler et al., 1992; Vjestica et al., 
2013), allowing a tight regulation of protein quality control during stress conditions.  
CHIP was shown to directly interact with HSF1 upon stress induction, co-translocating from the 
cytoplasm to the nucleus and thereby increasing HSP70 expression in non-neuronal cell types 
like fibroblasts, HEK cells and retinal epithelium cells, with no or a reduced response in CHIP-/- 
or CHIPmut cells (Dai et al., 2003; Kim et al., 2005; Qian et al., 2006).  Furthermore, CHIP 
expression is required for HSP70 turnover upon recovery (Qian et al., 2006). Dai and colleagues 
also showed that HSP70 expression upon heat shock in CHIP-/- mice was strongly reduced 
compared to wildtype in most tissues, with almost complete absence of HSP70 in brain, heart 
and spleen (Dai et al., 2003).  
To understand the pathomechanism induced by mutant STUB1, we assessed HSR in fibroblasts 
of 3 SCAR16 patients and 3 healthy controls and found an impaired HSR in patients. To reflect 
the central nervous system as the major focus of disease in SCAR16, we next investigated HSR in 
cortical neurons (CN) generated from iPSCs. While heat stress resulted in increased transcript 
levels of HSPs, this surprisingly did not translate into higher protein levels of HSP70. Proteomic 
analysis of patient and control CN showed disturbances in protein folding, the ubiquitin system 
and oxidative stress response. Both approaches question the role of impaired HSR in SCAR16 
neuropathology and highlight the need for careful selection of proper cell types for disease 
modelling. 
MATERIALS & METHODS 
Patients  
Three patients with genetically confirmed compound heterozygous or homozygous mutations 
in STUB1 were included in this study. Patient STUB1_1 had a homozygous c.367C>G; p.L123V 
mutation whereas patients STUB1_2 and STUB1_3 carried compound heterozygous mutations 
c.355C>T; p.R119*; c.880A>T, p.I294T and c.433A>C, p.K145Q; c.728C>T, p.P243L, respectively 
(Hayer et al., 2017). All patients were severely affected by SCAR16 with ataxia (3/3), spasticity 
(3/3), epilepsy (2/3), dementia (2/3) and hypogonadism (1/3). The controls were age- and gender-
matched for fibroblast analyses and gender-matched for induced pluripotent stem cell (iPSC)-
derived neuronal analyses. Detailed information on study participants and cell lines is provided 
in Supplementary Table S1. The study has been approved by the Ethics Committee of the 
University of Tübingen (vote 598/2011BO1). Informed written consent was obtained from all 
participants or their legal guardian.  
Fibroblast cultivation 
Human dermal fibroblasts were obtained from skin biopsies and maintained at 37°C, 5% CO2 
and 100% relative humidity in fibroblast medium consisting of Dulbecco’s Modified Eagle 
Medium (DMEM) (Merck Millipore) supplemented with 10% fetal bovine serum (FBS) (Thermo 
Fisher Scientific) in cell culture flasks. Upon reaching high confluency, cells were split by 
washing with PBS followed by 5 min trypsination and passaging into new flasks or seeding at a 
defined density depending on the assay (20.000 cells / cm2 for immunocytochemical analysis; 
30.000 cells / cm2 for protein analysis).   
Reprogramming of fibroblasts to iPSCs 
Induced pluripotent stem cells were generated from fibroblasts according to a previously 
published protocol (Okita et al., 2011) with minor modifications. In brief, 105 human dermal 
fibroblasts were nucleofected with 1 µg of each episomal plasmid (pCXLE-hUL, pCXLE-hSK and 
pCXLE-hOCT4 (Addgene)) with Nucleofector 2D (Lonza). Fibroblasts were cultivated in 
fibroblast medium before adding 2 ng/ml FGF2 (Peprotech) on day 2. The following day, medium 
was changed to Essential 8 (E8) medium [DMEM/F12 (Life Technologies), 64 mg/l L-Ascorbic 
acid 2-phosphate magnesium (Sigma Aldrich), 1% ITS-Supplement 100x (Life Technologies), 10 
ng/ml FGF2, 2 ng/ml TGFß1 (Peprotech), 100 ng/ml Heparin (Sigma Aldrich)] with 100 μM NaB 
(Sigma-Aldrich). After 3–4 weeks with medium change every other day, colonies were manually 
picked and expanded onto Matrigel-coated plates (Corning) in a feeder-free system in E8 
medium. iPSCs were frozen in E8 medium with 40% KO-SR (Life Technologies), 10% DMSO 
(Sigma Aldrich) and 10 μM Y-27632 (Selleckchem). Genomic integrity was confirmed by 
excluding plasmid integration and performing whole genome SNP genotyping (Infinium 
OmniExpressExome-8-BeadChip (Illumina) or CytoScan HD technology (Affymetrix)), Copy 
number analysis (CNVPartition plugin (Illumina)), and resequencing of the mutation sites. 
Pluripotency was confirmed by ALP expression, immunocytochemical analysis of pluripotency 
markers, transcript analysis of pluripotency genes and embryoid-body based differentiation of 
iPSCs into cells of all 3 germ layers. For detailed descriptions, see (2018).  
Targeted STUB1 Knockout with CRISPR/Cas9 
To generate the STUB1 knockout line STUB1(-/-), we targeted exon 2 and 3 of STUB1 in a dual-
cleavage approach to enhance efficiency of knockout generation. Crispr-RNAs (crRNAs) 
(Integrated DNA Technologies) were designed with the CRISPOR web-tool (Haeussler et al., 
2016). iPSCs of control line CO5 were nucleofected with two crRNA-ATTO550-tracrRNA 
(Integrated DNA Technologies) ribonucleoprotein (RNP) complexes with Cas9 protein 
(Integrated DNA Technologies) followed by fluorescence-activated cell sorting (FACS) of 
ATTO550+ cells with Sony Cell Sorter SH800Z, single cell seeding and manual picking and 
expansion of clones. Homozygous or heterozygous knockout was validated by PCR analysis and 
Sanger Sequencing. Top 5 exonic off-target effects as predicted by CRISPOR for each cleavage 
site were excluded by Sanger sequencing in the isogenic control as well as the generated clones. 
For detailed experimental setup and characterization of STUB1(-/-), see (Schuster et al., 2019).   
Neuronal differentiation 
To model SCAR16 in vitro, we generated neurons of cortical layer V and VI according to a 
published protocol (Shi et al., 2012; Rehbach et al., 2019) with modifications. In brief, iPSCs were 
dissociated with 0.02% EDTA (Carl Roth) in PBS (Sigma Aldrich) and seeded at a density of 
3 × 105/cm2 in E8 medium supplemented with 10 µM Y-27632. The following day, medium was 
replaced by neural induction medium (1:1 N2/B27, 500 nM LDN-193189 (Th. Geyer), 10 µM 
SB431542 (Sigma Aldrich)) with medium change every day. The neural induction medium was 
supplemented with 20 ng/ml FGF2 on day 8. The next day, cultures were split by detachment 
with Accutase (Sigma Aldrich) for 10 min and seeded in N2/B27 medium with 20 ng/ml FGF2 
and 10 µM RI onto Matrigel-coated 6 well plates. N2/B27 medium with 20 ng/ml FGF2 was added 
on the next day. From day 11 onward, cells were cultured in N2/B27 medium with medium 
change every other day. Neural precursors were dissociated and frozen on day 19. For 
maturation, frozen precursors were thawed and seeded in N2/B27 medium with 10 µM Y-27632, 
with medium change every other day. On day 26, cells were detached with Accutase and 
reseeded at the desired assay density (for immunocytochemical staining: 1 x 105/cm2; for protein 
and RNA isolation: 4-6 x 105/cm2) on Poly-L-Ornithine (Sigma Aldrich) and Matrigel-coated 
wells. On day 27 and 29, medium was changed to N2/B27 supplemented with 10 µM PD0325901 
(Tocris) and 10 µM DAPT (Sigma Aldrich). From day 31 and up to the analysis on day 36, the cells 
were cultured in N2/B27 medium with medium changes every other day.   
For heat shock experiments, cells were exposed to 42.5°C with prewarmed medium for 1h, with 
direct harvesting of cells for RNA isolation and protein fractionation and an additional 4, 8 or 
24h recovery at 37°C for protein analysis.  
Immunocytochemistry and image analysis 
Cells were washed with PBS followed by fixation with 4% paraformaldehyde (PFA, Merck 
Millipore) and subsequent washing. Fixed cells were permeabilized and blocked with 5% BSA 
(Sigma Aldrich) in PBS with 0.1% Triton-X100 (Carl Roth). Afterwards, cells were stained with: 
anti-ß-III-tubulin (TUJ, mouse, 1:1000, T8660, Sigma Aldrich), anti-CTIP2 (rat, 1:200, ab18465, 
Abcam), anti-HSF1 (rabbit, 1:500, 4356T, Cell Signaling Technology) and/or anti-HSP70 (mouse, 
1:500, ADI-SPA-810, Enzo Life Sciences); all followed by Alexa-Fluor conjugated secondary 
antibodies (Invitrogen). Hoechst 33258 staining (1:10.000, H1398, Invitrogen) was used to 
counterstain for nuclei. Coverslips were mounted with Dako Mounting Solution (Agilent Dako) 
onto microscope slides. 4-5 random fields per coverslip per cell line were used for quantification. 
Images were acquired using Observer Z1 fluorescence microscope (Carl Zeiss), exposure time 
was kept constant. Quantifications were conducted with the cell counter plugin in FiJi 
(Schindelin et al., 2012) and threshold mask settings in ImageJ (https://imagej.nih.gov/ij/).  
Transcript analysis by qRT-PCR 
For RNA isolation, cells were scraped off in RLT buffer (Qiagen) and lysed in the well. RNA was 
isolated with RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. A total of 
500 ng RNA was reverse-transcribed into cDNA with RevertAid First Strand cDNA Synthesis Kit 
(Thermo Fisher Scientific) according to manufacturer’s instructions. For real-time polymerase 
chain reaction, 3 µl of 1.25 ng/µl cDNA was mixed with 2 µl of 2 µM primer pairs and 5 µl of SYBR 
Green Select Master Mix (Applied Biosystems). Primers are listed in Supplementary Table S2. 
The qRT-PCR program was as follows: 50°C for 2 min, 95°C for 2 min, followed by 40 cycles of 
95°C for 1s, 60°C for 30s and 72°C for 5s, and subsequently 95°C for 15s, 60°C for 1 min and 95°C 
for 15s. Specificity of PCR products was confirmed by melting curve analysis. Real-time PCR 
amplifications were performed on the Viia7 Real-Time PCR System (Applied Biosystems) and 
primers were run in triplicate. The house-keeping genes GAPDH and TBP were amplified to 
standardize the amount of sample cDNA. Analysis was performed with QuantStudio Software 
V1.3 (Thermo Fisher Scientific).  
Cell viability analysis 
Fibroblasts were seeded at a density of 12.5 x 104/cm2 on 96 well plates in triplicate, CNs were 
seeded at a density of 3 x 105/cm2 on D33 on 96 well plates coated with Poly-L-ornithine and 
Matrigel in quadruplicate. To assess cell viability upon heat shock, CyQuant Direct Cell 
Proliferation Assay (Thermo Fisher Scientific) was used according to manufacturer’s 
instructions. In brief, CQD nucleic acid stain and CQD background suppressor dye were diluted 
in PBS and added to the cells, followed by 1h incubation at 37°C. 1% Triton-X100 was used as 
negative control for cell viability. The plate reader SpectraMax M (Molecular Devices) was set to 
42.5°C or 44°C and plates were measured for 6h with excitation/emission at 485/525 nm.  
Protein isolation 
Pellets of primary fibroblasts or CNs were lysed in RIPA buffer (Sigma Aldrich) containing 1x 
cOmplete protease inhibitor cocktail (PI) (Roche) for 45 min on a rotator at 4°C. Cell debris was 
pelleted at 15.800 x g at 4°C for 30 min. Protein concentration was determined using the Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific) according to manufacturer's instructions.  
Subcellular fractionation 
To separate nuclei from cytoplasm in CNs, a protocol by Abcam with slight modifications was 
applied. In brief, cells were scraped off on ice in fractionation buffer [20 mM HEPES (pH 7.4) 
(Carl Roth), 10 mM KCl (Carl Roth), 2 mM MgCl2 (Merck Millipore), 1 mM EDTA (Carl Roth), 1 
mM EGTA (AppliChem), 1 mM DTT (AppliChem), 1 x PI] and incubated for 15 min on ice. 
Samples were then passed through a 27 gauge needle (Sigma Aldrich) 10 times followed by 20 
min incubation on ice. Samples were centrifuged at 750 x g for 5 min at 4°C and supernatant 
containing cytoplasm was transferred to a fresh tube.  ¼ of the total amount of 5x RIPA buffer 
[750 mM NaCl (VWR), 5% Igepal CA-630 (Sigma Aldrich), 2.5% Sodium deoxycholate (Carl 
Roth), 0.5% SDS (Sigma Aldrich), 250 mM Tris (pH 8.0) (AppliChem)] with 1 x PI was added. 
The nuclear pellet was washed with fractionation buffer followed by 10 more passes through a 
27 gauge needle and 10 min centrifugation at 750 x g, 4°C. The supernatant was discarded, the 
pellet was resuspended in 1x RIPA buffer + PI and sonicated to shear genomic DNA. Protein 
isolation was followed according to the procedure described above.  
Western blotting and densitometric analysis 
10-30 µg of protein was eluted in 5 x Pink buffer (Thermo Fisher Scientific) at 95°C. Samples were 
separated on 10% polyacrylamide gels in 1 x NuPAGE MOPS SDS running buffer (Novex) and 
transferred onto a Hypond-P polyvinylidene difluoride (PVDF) membrane (Merck Millipore). 
Membranes were blocked in 5% milk in TBS-T, incubated overnight with primary antibodies: ß-
actin (mouse, 1:20.000, A5441, Thermo Fisher Scientific), CHIP (rabbit, 1:10.000, ab134064, 
Abcam), H3 (HRP-tagged, 1:100.000, ab21054, Abcam), HSF1 (1:1000), HSP70 (1:50.000), HSP90 
(mouse, 1:100.000, ADI-SPA-831-050, Enzo Life Sciences) in Western Blocking Reagent (Roche) 
at 4°C, followed by three washes with TBS-T and incubation with HRP-conjugated secondary 
antibodies (Jackson ImmunoResearch) for 1h at room temperature. Proteins were visualized 
using the Immobilon Western chemiluminescent HRP substrate (Merck Millipore). Bands were 
quantified with ImageJ and normalized to respective loading controls.  
RNA Sequencing analysis 
Isolated RNA at a concentration of 20 ng/µl was further purified with Illumina’s TruSeq mRNA 
v2Kit (polyA). Biological triplicates were sequenced on a HiSeq2500 using paired-end chemistry, 
2x125 cycles. The sequence depth was approx. 100 million reads per sample. Runs were performed 
at DeCODE genetics, Reykjavik, Iceland.   
To assess the differentiation state of generated CNs, cross-platform comparisons with spatio-
temporal data from developing human brain of the BrainSpan Atlas 
(https://www.brainspan.org) were performed by pairwise comparison of generated CNs with 
each BrainSpan Atlas sample. By ranking gene expression for each pairwise comparison, rank 
difference values for all genes were used to calculate Spearman Rank correlation coefficients. 
Wilcoxon’s rank-sum test was assessed if a category of interest (neocortex, subcortex, ganglionic 
eminence (GE), cerebellum) had significantly higher Spearman correlation coefficients than the 
background of all paired correlations. –Log 10 p-values of significant differences of CNs and 
spatio-temporal brain data were shown in heat maps.  
Mass spectrometry 
Equal amounts of samples were purified using SDS PAGE (Invitrogen). Coomassie-stained gel 
pieces were excised and in-gel digested using Trypsin as described previously (Borchert et al., 
2010). Extracted peptides were desalted using C18 StageTips and subjected to LC/MS-MS 
analysis, performed on an Easy nano-LC (Thermo Fisher Scientific) coupled to an LTQ Orbitrap 
Elite (Thermo Fisher Scientific) as decribed elsewhere (Franz-Wachtel et al., 2012). Equal 
amounts of the peptide mixtures were injected onto the column in HPLC solvent A (0.1% formic 
acid) at a flow rate of 500 nl/min and subsequently eluted with an 127 minute segmented 
gradient of 5–33-50-90% of HPLC solvent B (80% acetonitrile in 0.1% formic acid) at a flow rate 
of 200 nl/min. On Orbitrap Elite the 15 most intense precursor ions were sequentially 
fragmented in each scan cycle. In all measurements, sequenced precursor masses were excluded 
from further selection for 60 s. The target values were 5000 charges for MS/MS fragmentation 
and 106 charges for the MS scan. CNs of 3 controls (CO4, CO5, CO6) and 3 STUB1 patients 
(STUB1_1, STUB1_2 and STUB1_3) were analyzed.  
Mass spectrometry data processing  
The data was processed using MaxQuant software suite v.1.5.2.8 (Cox et al., 2008). Database 
search was performed in MaxQuant, using the Andromeda search engine (Cox et al., 2011). 
MS/MS spectra were searched against a target-decoy Uniprot database consisting of 95972 
protein entries from Homo sapiens and 245 commonly observed contaminants. Full specificity 
was required for trypsin, up to two missed cleavages were allowed. Carbamidomethylation of 
cysteine was set as fixed modification, oxidation of methionine and acetylation of the N-
terminus were set as variable modifications. Initial mass tolerance was set to 4.5 parts per million 
(ppm) for precursor ions and 0.5 dalton (Da) for fragment ions. Peptide, protein and 
modification site identifications were reported at a false discovery rate (FDR) of 0.01, estimated 
by the target/decoy approach (Elias et al., 2007). The label-free algorithm was enabled, as was 
the ‘match between runs’ option (Luber et al., 2010). Label-free quantification (LFQ) protein 
intensities from the MaxQuant data output were used for relative protein quantification. 
Downstream bioinformatical analysis (two-sample t-tests and Volcano plots) was performed 
using the Perseus software package, version 1.5.0.15.  Data was filtered for contaminants, reverse 
and only identified by site entries.  
 Statistical analysis  
All statistical analyses were performed using GraphPad Prism software (version 8). One-way 
ANOVA or a two-tailed t-test was applied. P-values were corrected for multiple comparisons 
and P < 0.05 was considered statistically significant. Unless indicated otherwise, all data is shown 
as mean ± standard error of the mean (SEM).  
RESULTS 
CHIP mutations do not alter viability of fibroblasts during prolonged heat stress  
As CHIP has been linked to cell viability upon heat shock, we assessed the effect of prolonged 
heat stress on viability of fibroblasts in 3 patients with STUB1 mutations (STUB1_1, STUB1_2, 
STUB1_3) in comparison to 3 healthy controls (CO1, CO2, CO3)(for further details, see Suppl. 
Table S1). For analysis, we exposed cells to either 42.5°C or 44°C for 6h and quantified the signal 
with the CyQuant Direct Cell Proliferation assay. Cell viability decreased rapidly between 3 and 
4 hours of prolonged heat stress at 42.5°C (Mean ± SEM (in %); 3h HS: 86.67 ± 9.16; 4h HS: 29.01 
± 1.15)(Fig. 1A). At 44°C, cell death mostly occurred after 2-3 hours of maintained heat shock (2h 
HS: 87.53 ± 3.16; 3h HS: 41.5 ± 6.95; 4h HS: 24.88 ± 0.54)(Fig. 1B). No consistent difference was 
detected between patients and controls. We therefore could not determine an effect of STUB1 
mutations on fibroblast viability upon prolonged heat stress.  
STUB1 mutations cause impaired heat shock response induction and recovery in 
fibroblasts 
Previous reports have shown that CHIP plays a role in both induction and recovery of the HSR 
in HEK and HeLa cells as well as fibroblasts. To test whether CHIP mutations lead to 
dysfunctional HSR, we analyzed HSF1 translocation upon heat shock, HSR induction by 
transcript analysis and protein expression analysis and HSR recovery by protein analysis in 3 
STUB1 patient- and 3 healthy age- and gender-matched control-derived fibroblasts.   
For the analysis of HSF1 translocation from cytoplasm to nucleus, we fixed cells after 1h heat 
shock at 42.5°C and immunocytochemically stained for HSF1, HSP70 and Hoechst (Fig. 2A). In 
all 6 cell lines (3 patients, 3 controls), HSF1 and HSP70 protein was barely detectable in 
unstressed conditions. Upon heat shock, HSF1 levels in the nuclei strongly increased and HSP70 
accumulated in nuclear bodies. Adding 4h of recovery at 37°C, HSF1 levels in the nuclei returned 
to baseline, but cytosolic expression of HSP70 increased strongly. Representative images of 2 cell 
lines are shown in Figure 2A. Upon quantification of nuclear HSF1 levels at 1h of heat shock, we 
saw a trend towards lower HSF1 levels in patients compared to controls (Mean ± SEM (in %), 
Controls: 92.3 ± 5.0; Patients: 80.0 ± 4.5; P = 0.09)(Fig. 2B).   
Analyzing transcripts of heat shock-related genes, we saw a strong increase of HSPA1A/B (coding 
for HSP70) and DNAJB1 (coding for HSP40) upon 1h of heat shock (Fig. 2C, D). This induction, 
however, was significantly lower in patients compared to controls (Mean ± SEM; HSPA1A/B: 
controls: 31.89 ± 1.39 fold, patients: 11.44 ± 5.25 fold (P = 0.004); DNAJB1: controls: 6.17 ± 0.25 fold, 
patients 2.42 fold ± 0.71 (P = 0.001)). Levels in controls and patients decreased with additional 
4h of recovery. HSPB1 (coding for HSP27) and HSPB8 (coding for HSP22) transcription slightly 
increased upon recovery (HSPB1: controls: 1.86 ± 0.1 fold, patients: 1.56 ± 0.25 fold; HSPB8: 
controls: 2.61 ± 0.09 fold, patients 1.86 ± 0.27 fold (P = 0.10)) (Fig. 2C, D). HSP90aa1 (HSP90), 
HSPA8 (HSC70) and HSPA5 (BiP/GRP78) were neither strongly altered upon heat shock or 
recovery nor different between patients and controls (Suppl. Fig. S1).  
On protein level, we saw low levels of HSP70 under basal conditions in all cell lines and a strong 
induction of HSP70 at 1h hs + 4h recovery (Mean ± SEM; unstressed controls: 1 ± 0.23; 1h hs + 4h 
recovery Controls: 6.03 ± 0.36; unstressed patients: 1.67 ± 0.33; 1h hs + 4h recovery patients: 7.34 
± 1.1). Induction was 6.0 fold in controls and 4.39 fold in patients (P = 0.1). However, HSP70 
turnover and thus HSR recovery differs in controls and patients with prolonged recovery times 
with significantly higher HSP70 levels after 24h recovery in patients (Controls: 2.88 ± 0.76; 
Patients: 7.07 ± 1.55; P = 0.0004).  
In summary, we were able to show that HSF1 translocates to the nucleus upon heat shock in 
fibroblasts with a slight but not significant reduction caused by STUB1 mutations. This led to a 
significantly lower induction of HSPA1A/B and DNAJB1 in patients. HSP70 protein levels were 
strongly induced at 1h hs + 4h recovery compared to unstressed levels in both patients and 
controls, but levels in patients remained high at 8h and 24h after heat shock, indicating an 
impaired HSR recovery and HSP70 turnover.    
iPSC-derived cortical neurons show typical morphology and express neuronal markers 
As SCAR16 primarily affects the central nervous system, we next investigated the HSR in cortical 
neurons. For this, we generated induced pluripotent stem cells from three SCAR16 patients 
(STUB1_1, STUB1_2, STUB1_3) and three gender-matched healthy controls (CO4, CO5, CO6)(for 
further details, see Suppl. Table S1). Genomic integrity and pluripotency was confirmed for all 
cell lines (data not shown; for details, see (Schuster et al., 2018)). Additionally, we generated a 
STUB1 knockout line STUB1(-/-) by CRISPR/Cas9-mediated genome editing from the isogenic 
control line CO5 (Schuster et al., 2019). iPSCs were differentiated into cortical neurons according 
to a previously published protocol with slight modifications (Shi et al., 2012; Rehbach et al., 
2019)(Fig. 3A). After 36 days of differentiation, the cultures were highly homogeneous, with all 
cells being positive for ß-III-tubulin (TUJ) and with >75%  of cells being positive for CTIP2 (Mean 
± SEM, 86.7 ± 1.3%), a cortical layer V marker (Fig. 3B). There was no significant difference in 
the percentage of CTIP2-positive nuclei between STUB1 patients, knockout and controls.  
To assess the spatial and temporal identity of the generated CNs and to exclude differences in 
differentiation potential and state, we compared transcript analysis data of biological triplicates 
of CO4, CO5, STUB1_2 and STUB1_3 with transcript data of the human developing brain (Human 
BrainSpan atlas, http://www.brainspan.org, data from fetal and early childhood postmortem 
tissue up to 1 year of age). The gene signature of both patients’ and controls’ iPSC-derived cortical 
neurons most significantly matched the co-expressed gene sets in neocortex and subcortex at 
post conception week (pcw) 12 to 21 with the strongest correlation at pcw 16 (Fig. 3C). The 4 
analyzed cell lines display only slight differences in the expression patterns independent of 
STUB1 mutations and show the same temporo-spatial pattern.  
In generated CNs, we quantified STUB1 transcript levels and CHIP protein expression levels. On 
transcript level, patients STUB1_1 and STUB1_3 showed no difference to controls (Fig. 3D) while 
on protein level, CHIP expression was reduced in both patient CNs to 25% of control levels (Fig. 
3E). STUB1_2 neurons showed a reduced STUB1 transcript level to 25% (Fig. 1D) resulting in an 
even lower protein level of 15% compared to wild-type (Fig. 3E). STUB1(-/-) showed a transcript 
level of 3% compared to controls (Fig. 3D), and no detectable protein (Fig. 3E), confirming the 
homozygous knockout of STUB1.  
CHIP mutations do not alter cell viability during prolonged heat stress in cortical 
neurons 
To examine the effect of heat shock on viability of CNs, we exposed CNs of 3 controls, 3 STUB1 
patients and STUB1(-/-) to prolonged heat stress of either 42.5°C or 44°C for 6 h. Interestingly, 
signal intensity of the CyQuant Direct Cell Proliferation Assay slightly increased in all cell lines 
at 42.5°C and only reached levels below baseline after more than 4h of heat stress. Upon 6h of 
heat stress a mean value of 85.5 ± 11.1% of viable cells was reached (Fig. 4A). At 44°C, lethality of 
CNs was higher, reaching a mean value of 55.0 ± 10.3% of viable cells after 6h of heat stress (Fig. 
4B). No consistent difference in cell viability was observable between controls, patients and the 
STUB1(-/-) line. 
Mutations in STUB1 do not impair the heat shock response in cortical neurons  
We next investigated the HSR in CNs after 1h of heat shock at 42.5°C. To assess nuclear 
translocation of HSF1 we performed subcellular fractionation of nucleus and cytoplasm. Proper 
separation of nuclei from the cytoplasmic fraction was verified by presence and absence of 
histone 3 (H3), respectively (Suppl. Fig. S2A). In unstressed conditions, HSF1 was highly 
expressed in the cytosol and weakly expressed in the nucleus. Upon heat shock, HSF1 got 
hyperphosphorylated as seen by a mass shift and translocated to the nucleus (Fig.5A), since 
almost no HSF1 remained in the cytosol after heat shock. HSF1 translocation and expression 
levels were not altered by mutant STUB1 (Fig. 5A). CHIP levels were shown to diminish after 
heat shock in the cytosol in controls but did not increase drastically in the nucleus.   
On transcript level, heat strongly induced the transcription of HSPA1A/B (encoding HSP70) and 
DNAJB1 (encoding HSP40) (Fig. 5B, C). This induction was significantly higher in patients and 
STUB1(-/-) compared to controls (Mean ± SEM; HSPA1A/B in controls: 12.06 ± 1.18 fold, in 
patients: 21.38 ± 3.25 fold (P = 0.017) and in STUB1(-/-): 24 fold (P = 0.03); DNAJB1 in controls 
11.06 ± 0.46 fold, in patients: 17.28 ± 2.9 fold (P = 0.038) and in STUB1(-/-) 18 fold (P = 0.1)). After 
4h of recovery levels decreased in all lines again (HSPA1A/B in controls: 7.31 ± 0.54 fold, in 
patients: 10.26 ± 1.81 fold, in STUB1(-/-) 6.3 fold; DNAJB1 in controls: 2.40 ± 0.22 fold, in patients: 
2.58 ± 0.61 fold, in STUB1(-/-): 1.7 fold). HSPB1 (encoding HSP27) and HSPB8 (encoding HSP22) 
transcription slightly increased upon heat shock by 2-4 fold but highly increased after 4h 
recovery at 37°C (HSPB1 in controls: 28.16 ± 7.86 fold, in patients: 11.25 ± 2.05 fold (P = 0.037) , in 
STUB1(-/-): 15.3 fold (P = 0.3); HSPB8: in controls: 98.5 ± 57.65 fold, in patients: 4.5 ± 0.7 fold (P 
= 0.11), in STUB1(-/-): 5.7 fold (P = 0.3)). The increase of HSPB1 was significantly higher in controls 
compared to patients. However, variability for HSPB1 and HSPB8 was very high in between lines, 
probably caused by low basal expression levels. HSP90aa1 (HSP90), HSPA8 (HSC70) and HSPA5 
(BiP/GRP78) were neither strongly altered upon heat shock or recovery nor different between 
patients and controls (Suppl. Fig. S2B, C).    
Unexpectedly, on protein level, HSP70 expression under basal conditions was already very high 
in CNs, with slight variations between lines and independent of STUB1 mutations (Suppl. Fig. 
S2D). We barely saw an increase of HSP70 after heat shock and various times of recovery 
(increase upon 1h hs + 4h recovery normalized to baseline (Mean ± SEM) of controls: 1.27 ± 0.3 
fold; patients: 1.12 ± 0.15 fold; STUB1(-/-): 1.25 fold). However, comparing absolute HSP70 levels, 
we saw a slightly lower levels in patients compared to controls (unstressed HSP70 level of 
controls: 1 ± 0.16, patients: 0.47 ± 0.07, P = 0.27; STUB1(-/-): 0.58; 1h hs + 4h recovery HSP70 level 
of controls: 1.22 ± 0.29, patients: 0.52 ± 0.07, P = 0.25; STUB1(-/-): 0.73) (Fig. 5D).  
In summary, we were able to show that HSF1 translocates to the nucleus upon heat shock in CNs 
and leads to the induction of HSPA1A/B and DNAJB1 transcripts which surprisingly did not 
translate to increased HSP70 protein levels. Induction of HSPA1A/B and DNAJB1 was 
significantly higher in patients and STUB1(-/-) compared to controls. Furthermore, we barely 
saw an induction of HSP70 on protein level in both controls and patients.   
Proteome analysis of cortical neurons reveals impaired protein folding and 
ubiquitination in patients 
Proteomic analysis based on mass spectrometry with LC/MS-MS and label-free quantification 
was applied to identify quantitative differences in proteome-wide protein levels between CNs of 
controls and patients (N=3 for both biological groups). We identified 53 proteins with 
significantly altered levels (Fig. 6A); 28 proteins were increased (Fig. 6B, upper panel) and 25 
proteins were reduced in controls compared to patients (Fig. 6B, lower panel). Additionally, 185 
proteins were exclusively expressed in at least 2 control cell lines but in no patient cell line 
(Suppl. Table S3) and 228 proteins were exclusively expressed in at least 2 patient cell lines but 
in no control cell line (Suppl. Table S4). Based on Webgestalt analysis (Liao et al., 2019) of 
proteins that were exclusively expressed in at least 2 controls, gene ontology (GO) terms of 
protein folding and refolding and the ubiquitin system were highly enriched (Fig. 6C, left panel). 
Oppositely, GO terms of oxidative stress coping were enriched in patients only (Fig. 6C, right 
panel). Considering specific interaction partners of CHIP, we found differences between controls 
and patients for some proteins including PSEN1/2, IGF1R, TRAF2 and TRAF6 (Suppl. Fig. S3). 
DISCUSSION 
Proteotoxic stress and a compromised HSR is associated with many neurodegenerative diseases 
such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease or amyotrophic lateral 
sclerosis (reviewed by San Gil et al., 2017). This suggests an innate susceptibility of neurons to 
stress, homeostatic changes and disturbances in protein quality control and highlights the 
significance of chaperones in neuroprotection.   
In the present study, we investigated the pathological effect of STUB1 mutations causing SCAR16 
on the HSR. Analyzing patient-derived fibroblasts, we confirmed an impaired HSR induction on 
transcript level and an impaired HSR recovery on protein level. Furthermore, we developed a 
human iPSC-based SCAR16 disease model to properly model the disease in cortical neurons as 
the affected cell type. Despite differences on heat-inducible transcript levels in STUB1-mutant 
cortical neurons, we could not detect an impaired heat shock induction or recovery in CNs of 
STUB1 patients on protein level.   
In a rodent model of SCAR16, CHIP-/- mice exhibit decreased stress tolerance, pronounced heat 
sensitivity, increased oxidative stress and lethality upon heat shock (Dai et al., 2003; Min et al., 
2008). In vitro, CHIP knockdown in mesodermal cell lines caused reduced cell viability upon 
prolonged heat stress and impaired induction and recovery of the HSR (Dai et al., 2003; Kim et 
al., 2005; Qian et al., 2006; Zhang et al., 2015).   
In human SCAR16 cell models we found a striking difference in heat stress tolerance between 
cell types. Whereas less than 30% of fibroblasts survived 4h of heat shock at 42.5°C, more than 
95% of neurons were still viable. This might indicate a higher stress vulnerability of fibroblasts 
and a stronger response to this toxic stimulus. While Dai and colleagues (2003) reported 50% 
lethality of murine CHIP(-/-) fibroblasts at 60min of 42°C, our patient-derived fibroblasts did 
not show relevant lethality after 60min of heat shock at 42.5°C. This difference might be due to 
small levels of CHIP remaining in patient fibroblasts with some residual activity which 
potentially rescues the drastic toxic effect seen in complete CHIP knockout fibroblasts. Our data 
implies that STUB1 mutations and thereby dysfunctional CHIP do not affect the cell viability 
negatively upon heat shock in fibroblasts and CNs.   
We next evaluated the induction of HSR and its recovery in patient- and control-derived 
fibroblasts. By immunocytochemical analysis of heat shocked cells, we could show that HSF1 
translocated to the nucleus in patients and controls, with a trend towards lower levels in 
controls. Furthermore, analyzing different transcript levels in fibroblasts, we observed a lower 
increase in HSPA1A/B and DNAJB1 transcript levels upon heat shock in patients compared to 
controls. This might be caused by slightly lower nuclear HSF1 levels or by differential 
posttranslational modifications (PTMs) of HSF1, as PTMs were reported to strongly alter the 
activity of HSF1 (reviewed by Gomez-Pastor et al., 2018). On protein level, surprisingly, we do 
not see a reduced HSP70 level in patients compared to controls after 4h recovery from heat 
shock as it would be expected from the lower transcript levels but a 6-7 fold increase in both 
biological groups. Yet, we see an impaired HSR recovery, as indicated by remaining high levels 
of HSP70 after prolonged recovery (8 and 24h), in line with the results by Qian and colleagues 
(2006). This leads to the conclusion that either HSP70 ubiquitin tagging is reduced because 
CHIP is mutated or that the amount of misfolded proteins in patients is simply higher, requiring 
a prolonged higher expression of HSPs in those cells, or a combination of both. In conclusion, 
we confirm an impaired induction and recovery of HSR caused by dysfunctional CHIP, though 
for the first time in patient-derived cells.  
As SCAR16 primarily causes degeneration of the central nervous system, we next sought to 
analyze the HSR in patient neurons. We therefore generated patient-specific iPSCs from 
fibroblasts and differentiated those, together with gender-matched controls, into cortical 
neurons as a disease-relevant cell type. This provides a disease model with endogenous protein 
levels and the patient’s own genetic background.   
We could show that the translocation of HSF1 from the cytoplasm to the nucleus upon heat 
shock occurs invariable of CHIP functionality, suggesting no direct impact of CHIP mutations 
on trimerization of HSF1 or its translocation in CNs. CHIP levels declined upon heat shock in 
the cytoplasm, but did not correspondingly increase in the nucleus. Potentially, nuclear CHIP 
levels did already return to baseline in our experimental setup with 1h heat shock, as Anderson 
and colleagues showed a strong accumulation in the nucleus only 5-10 minutes after heat shock 
and a decrease back to baseline within 30-60 mins (Anderson et al., 2010).  
Analyzing transcript levels of heat shock proteins, we observed a higher increase in HSPA1A/B 
and DNAJB1 transcript levels upon heat shock in patient neurons compared to controls, 
independent of nuclear HSF1 levels. This might be caused by differential PTMs of HSF1 as 
described above. Higher HSPA1A/B and DNAJB1 transcription might also be caused by ‘pre-
conditioning’ to stress and thermotolerance in patients: Levels of misfolded proteins are 
presumably higher in CHIP mutant cells, causing mild proteotoxic stress and an induction of 
HSR prior to the heat stimulus which potentiates the HSR upon subsequent stress exposure 
(Burdon, 1987). Stress pre-conditioning might only play a role in cortical neurons and not in 
fibroblasts as non-dividing cells are more vulnerable to proteotoxic stress in general.  
Transcript levels of the small HSPs (sHSPs) HSPB1 (coding for HSP27) and HSPB8 (coding for 
HSP22) were strongly increased at recovery steps of heat shock, indicating two stages of 
transcript induction with an early induction of HSPA1A/B and DNAJB1 and, unexpectedly, a 
delayed induction of HSPB1 and HSPB8. HSP27 and HSP22 bind to unfolded proteins, prevent 
their aggregation and protect cells from toxicity caused by aggregates. Both sHSPs also enable 
stress resistance and inhibit apoptosis (Acunzo et al., 2012). This might be the explanation for 
higher levels in controls compared to patients and a delayed induction. Interestingly, mutations 
in both HSPB1 and HSPB8 induce neurodegeneration, highlighting the importance of both 
sHSPs in the stress response in neurons in particular.  
On protein level, unexpectedly, we neither detected a prominent induction of HSP70 protein 
nor a difference in HSP70 level upon recovery. HSP70 levels at 4h recovery after heat stress were 
only 1.1 – 1.2 fold higher than its basal levels, compared to 6-7 fold higher levels in fibroblasts. 
This might have several reasons: 1) an impaired HSR in the brain might be relevant and disease-
causing but not in neurons, 2) alterations of the HSR that were seen in patient-derived 
fibroblasts but not in cortical neurons are not disease-relevant, as the diseased cell type does not 
show any changes, or 3) the low HSR is an in vitro artifact of the monoculture and the culture 
conditions as the basal HSP70 level is already very high. As persistently high levels of HSP70 are 
detrimental to cells (Feder et al., 1992; Volloch et al., 1999), an additional induction of HSP70 
upon stress might be prevented in iPSC-derived cortical neurons.   
Considering the role of CHIP in this process, we observed only slightly lower HSP70 protein 
levels in patients but no difference in fold changes. Furthermore, the comparison of STUB1(-/-)  
with its isogenic control revealed very similar results as the comparison of patients and controls. 
This confirms our findings in patient lines and supports the limited effect of CHIP on the HSR 
in cortical neurons.   
While the HSR is evolutionarily well conserved, tissue and cell variability of the chaperome in 
humans is prominent: Hageman and Kampinga (2009) analyzed the temporal and the spatial 
expression pattern of 45 tissues using the Unigene database and observed strong tissue 
specificity for the expression of HSPH, HSPA and DNAJ isoforms. Notably, the expression of 
HSPA1A is highly variable between tissues and developmental stages (embryoid body to adult). 
Focusing on the brain, histological analyses after heat hock in rodents showed the strongest 
HSP70 induction in the dentate gyrus, hypothalamus and cerebellum (Blake et al., 1990; Li et al., 
1992). Of interest, comparison of HSR in neurons and glia in vitro revealed a higher induction of 
HSP70 in glial cells compared to neurons (Nishimura et al., 1991; Marcuccilli et al., 1996; Vogel 
et al., 1997; Batulan et al., 2003). This might be caused by differential co-chaperone levels: 
HSPBP1 expression in neurons is higher than in astrocytes and is directly linked to HSR 
inhibition (Zhao et al., 2017), HSPB1/HSP27 levels are oppositely correlated (Satoh et al., 1995). 
However, while HSP27 levels do not increase upon heat shock in astrocytes, this increase is 
observed in neurons (Satoh et al., 1995). Other HSPs such as DNAJB2A (HSP70 family) and 
HSJ1a/b (HSP40 family) were reported to be highly enriched in neuronal tissue (Cheetham et al., 
1992; Chapple et al., 2003). In our study, we additionally observed a strong cell specificity of 
HSPB1 and HSPB8, with higher expression under basal conditions in fibroblasts, but higher 
induction upon recovery of heat stress in neurons. This might point towards an important role 
of both small HSPs in stress coping in cortical neurons.   
For a broader picture, proteomic analysis of control and patient CNs was performed. 
Comparisons point towards aberrations in protein folding and the ubiquitin system as well as 
an increased oxidative stress level in unstressed patient cells. This is in line with reports that 
show that mutations alter CHIP’s ability to ubiquitinate its substrates (Heimdal et al., 2014; 
Ronnebaum et al., 2014; Pakdaman et al., 2017; Kanack et al., 2018; Shi et al., 2018). However, with 
more than 200 E3 ligases encoded in the human body, substrates are not exclusively 
ubiquitinated by one E3 ligase, but e.g. Parkin and CHIP act redundantly on some substrates 
(Morishima et al., 2008). Furthermore, keeping in mind the function of CHIP in tagging 
misfolded proteins with ubiquitin for degradation, the importance of CHIP might only show up 
in a state with high abundancy of misfolded proteins.   
In summary, our results question the role of impaired HSR in SCAR16 neuropathology and point 
to protein degradation and oxidative stress as potentially more critical factors in the 
pathogenesis of CHIP-related neurodegeneration. By the demonstration of major differences in 
the HSR of fibroblasts and induced cortical neurons of SCAR16 patients this study highlights the 
need for careful selection of proper cell types for modelling human diseases.  
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FIGURES 
 Figure 1 | Cell viability of fibroblasts upon heat stress is not impaired by dysfunctional CHIP. Viability of 
fibroblasts in percent during prolonged heat stress at (A) 42.5°C and (B) 44°C for 6h of 3 controls and 3 STUB1 patients. 
Values are given as mean of triplicates. Triton X-100 was used as negative control for cell viability. 
  
 
Figure 2 | Mutant CHIP impairs HSR induction and recovery in fibroblasts. (A) Immunocytochemical staining 
of HSF1 (red), HSP70 (green) and Hoechst (blue) of fibroblasts without stress, after heat shock (1h, 42.5°C) and after 
recovery (4h 37°C). Exemplary images of 1 control and 1 patient are shown. Scale bar 50 µm. (B) Quantification of 
HSF1 levels in nuclei of heat shocked fibroblasts, given in percent normalized to CO1. (C) Transcript analysis by qRT-
PCR of HSPA1A/B, DNAJB1, HSPB1 and HSPB8 in unstressed, heat shocked (HS) and recovered (R) samples. Values 
are normalized to CO1 and the housekeeping genes GAPDH and TBP. N=3 replicates (mean ± SEM). (D) Pooled 
analysis of 3 controls and 3 patients. Transcript levels were normalized to the respective basal levels. ** p<0.01, One-
way ANOVA. (E) Western blot analysis of HSP70 protein levels of fibroblasts without stress, after 1h HS and up to 24 
h of recovery with ß-actin as the loading control. One representative image out of three experiments is shown. 
Quantification is based on the normalization to unstressed controls, 3 controls and 3 patients were pooled. *** 
p<0.001, One-way ANOVA.  
  
  
Figure 3 | Characterization of iPSC-derived neurons. (A) Schematic representation of the experimental procedure 
of the differentiation of induced pluripotent stem cell (iPSCs) into iPSC-derived cortical neurons (CNs). (B) 
Immunocytochemical stainings of CNs on D36 for TUJ (green) and CTIP2 (red). Scale bar: 50 µm. Exemplary stainings 
of 3 lines are shown here. Quantification of percentage of CTIP2+/DAPI+ cells in controls, patients and STUB1(-/-) was 
performed for 4-5 fields per cell line. Values are given as Boxplots showing Min to Max, with the mean indicated by a 
line. (C) Transcript expression in CNs match best expression found in neocortical tissue at post conception week 16. 
Heatmaps were produced for 2 controls (CO4, CO5) and 2 patients (STUB1_2; STUB1_3) by Wilcoxon’s rank-sum 
comparisons of CN transcripts to the BrainSpan Atlas. All 4 generated lines display a similar expression pattern. (D) 
Transcript level of STUB1 in 3 controls, 3 patients and the homozygous knockout line. Levels are normalized to CO4. 
Values are given as mean ± SEM. Dotted lines indicate full level and 50% reduced transcript levels. (E) CHIP protein 
expression level was analyzed by Western Blotting. One representative blot is shown. Bands are quantified 
densitometrically and normalized to ß-actin and CO4. Values are given as mean ± SEM. N=3. iPSC: induced 
pluripotent stem cells; CN: iPSC-derived cortical neurons; GE: ganglionic eminence; pcw: post conception week. 
  
 Figure 4 | Viability of cortical neurons upon heat shock is not impaired by dysfunctional CHIP. Cell viability 
[in %] during prolonged heat shock at (A) 42.5°C and (B) 44°C has been investigated in 3 control, 3 STUB1 patient and 
a STUB1(-/-) line. Values are given as mean of triplicates. Triton X-100 was used as negative control for cell viability. 
  
 
Figure 5 | Mutant CHIP does not impair the HSR in iPSC-derived cortical neurons (CNs). (A) Cytoplasmic and 
nuclear fractions of HSP90, HSF1 and CHIP before and after heat shock (HS, 1h, 42.5°C) in CNs of 3 controls, 3 patients 
and STUB1(-/-). HSP90, HSF1 levels were quantified densitometrically and normalized to HSP90 and to CO5 / CO5 
HS. (B) Transcript analysis of HSPA1A/B, DNAJB1, HSPB1 and HSPB8 was performed by qRT-PCR. Values are 
normalized to CO5 and the housekeeping genes GAPDH and TBP. Each bar represents a triplicate with mean ± SEM. 
(C) Fold change of HSPs compared to baseline. Transcript levels of (B) were pooled for controls and patients. *: P<0.05; 
One-way ANOVA. (D) Western blot analysis of HSP70 levels of unstressed and heat shocked (HS) CNs with various 
times of recovery (R, in hours). HSP70 levels were quantified densitometrically and normalized to ß-actin. N=3 
Western blots were performed as technical replicates. 
  
Figure 6 | Proteome analysis of cortical neurons from 3 controls and 3 STUB1 patients revealed protein 
(re)folding disturbances and increased oxidative stress in patients. (A) The volcano plot illustrates significantly 
differentially expressed proteins in patients vs. controls. The –log10 t-test p-value is plotted against the t-test 
difference controls vs patients. The significance threshold is set to P = 0.05 / 1.30 (-log10). (B) Heat map displaying 
significantly dysregulated proteins, for proteins downregulated (upper panel) and upregulated in patients (lower 
panel). Values are given as LOG10 LFQ intensity, CO5 is set to 100%. (C) Gene ontology (GO) analysis with Webgestalt 
of proteins expressed in at least 2 of 3 controls but not in patients (left panel) and in at least 2 of 3 patients but not in  
controls (right panel). Proteins were subjected to GO classification in terms of molecular function. A threshold of 5 
proteins per classification was set. Enrichment ratios of GO terms are shown. GO: gene ontology.  
 
 
  
SUPPLEMENTARY FIGURES AND TABLES 
 
Suppl. Fig. S1: Transcript analysis of fibroblasts. (A) Transcript analysis of HSPA8, HSPA5 and HSP90aa1 was 
performed by qRT-PCR. Values are normalized to CO1 and the housekeeping genes GAPDH and TBP. Each bar 
represents a triplicate with mean ± SEM. (B) Fold change of HSPs compared to baseline. Transcript levels of (B) were 
pooled for controls and patients. 
  
 
Suppl. Fig. S2 | Mutant CHIP does not impair the HSR in iPSC-derived neurons. (A) Representative Western 
blot of cortical neurons derived from iPSC of CO6 demonstrating shift of HSF1 and HSP70 but not HSP90 from the 
cytoplasm to the nucleus upon heat shock (HS). Proper fractionation was verified for absence or presence of histone 
3 (H3) as a nuclear marker. (B) Transcript analysis of HSPA8, HSPA5 and HSP90aa1 was performed by qRT-PCR. 
Values are normalized to CO5 and the housekeeping genes GAPDH and TBP. Each bar represents a triplicate with 
mean ± SEM. (C) Fold change of HSPs compared to baseline. Transcript levels of (B) were pooled for controls and 
patients. (D) HSP70 protein expression was assessed in unstressed cells of 3 controls, 3 patients and STUB1(-/-). ß-
actin was used as loading control. Cyto: cytoplasm; Nucl: nucleus.  
 
 
  
 Suppl. Fig. S3 | Expression of selected CHIP interaction partners by proteomic analysis of iPSC-derived 
neurons. Protein of cortical neurons of 3 Controls and 3 STUB1 patients was analyzed by LC-MS/MS and analyzed 
with Perseus. Values are given as –LOG10 LFQ values.  
  
Suppl. Table S1 | Genetic characterization of SCAR16 patients, controls and generated homozygous 
knockout.  
Controls: CO1, CO2, CO3, CO4, CO5, CO6; Patients: STUB1_1, STUB1_2, STUB1_3; f: female; m:  male; F: fibroblasts; 
iPSC: induced pluripotent stem cells; CN: iPSC-derived cortical neurons. 
Cell line Cell type 
used 
Age at skin 
biopsy, sex 
Described mutations 
in STUB1 
Annotations 
CO1 F 28, m None None 
CO2 F 24, f None None 
CO3 F 22, m None None 
CO4 iPSC, CN 46, f None None 
CO5 iPSC, CN 37, f None None 
CO6 iPSC, CN 46, m None None 
STUB1_1 F, iPSC, CN 17, m c.367C>G, p.L123V 
(homozygous) 
symptoms: ataxia, 
spasticity 
STUB1_2 F, iPSC, CN 32, m c.355C>T, p.R119*; 
c.880A>T, p.I294T 
symptoms: ataxia, 
spasticity, dementia, 
epilepsy, hypogonadism 
STUB1_3 F, iPSC, CN 20, f c.433A>C, p.K145Q; 
c.728C>T, p.P243L 
symptoms: ataxia, 
spasticity, dementia, epilepsy 
STUB1(-/-)  iPSC, CN 37, f c.283-438del, 
p.V94Afs*5 
(homozygous) 
CRISPR/Cas9 induced homozygous 
knockout 
of STUB1 isogenic to CO5 
 
Suppl. Table S2 | qRT-PCR Primer 
Target gene Forward sequence Reverse sequence 
HSP90aa1 GCCCAGAGTGCTGAATACCC TTAACAGGTGCCCTGCTTCT 
HSPA1A/B GGTGCTGACCAAGATGAAG CTGCGAGTCGTTGAAGTAG 
HSPA8 CCCTTTATGGTGGTGAATGA GTAACAGTCTTCCCAAGGTAG 
HSPB1 AAGCTAGCCACGCAGTCCAA CGGCAGTCTCATCGGATTTT 
HSPB8 GCTTCAAGCCAGAGGAGTTGA ACAATGCCACCTTCTTGCTGT 
HSPA5/BiP CCCGAGAACACGGTCTTTGA TTCAACCACCTTGAACGGCA 
DNAJB1 CTGTCTTCTCTTTGGCCATCTC CTGCTGGAACGAGAGGTATTG 
STUB1 TCAAGGAGCAGGGCAATCGT CAGCGGGTTCCGGGTGAT 
GAPDH TCACCAGGGCTGCTTTTAAC GACAAGCTTCCCGTTCTCAG 
TBP CTTCGGAGAGTTCTGGGATTG CACGAAGTGCAATGGTCTTTAG 
 
Suppl. Table S3 | Proteins expressed in at least 2 control CNs and no patient CNs. Values are given in Log10 
LFQ intensity.  
Protein name CO4 CO5 CO6 STUB1_1 
STU
B1_2 
STU
B1_3 
AUP1 7,18 7,22 7,19 0 0 0 
EBF1/2/3 6,88 7,41 7,04 0 0 0 
SEC61A1 7,15 7,11 7,13 0 0 0 
FMNL2 7,02 6,99 7,12 0 0 0 
EML1 7,05 7,04 6,95 0 0 0 
CKMT1A 6,94 7,17 6,85 0 0 0 
SMPD3 6,80 7,10 7,04 0 0 0 
NDUFC2;NDUFC2-
KCTD14 6,92 6,98 7,04 0 0 0 
FN3KRP 6,99 7,00 6,89 0 0 0 
GABARAPL2 6,98 6,89 6,93 0 0 0 
MUC2;MLP 6,83 6,99 6,96 0 0 0 
ACTN4 6,94 6,95 6,89 0 0 0 
RPS10;RPS10P5 6,81 6,80 6,99 0 0 0 
TFAM 6,85 6,87 6,88 0 0 0 
STAT5B;STAT5A 6,85 6,78 6,81 0 0 0 
EVI5L 6,78 6,93 6,69 0 0 0 
STUB1 6,83 6,82 6,73 0 0 0 
STX1A 6,78 6,89 6,64 0 0 0 
CMIP 6,83 6,82 6,66 0 0 0 
TPPP 6,96 6,65 6,57 0 0 0 
PSMD9 6,85 6,72 6,67 0 0 0 
CELF3 6,69 6,86 6,63 0 0 0 
LGALSL 6,67 6,90 6,60 0 0 0 
RELN 6,73 6,57 6,86 0 0 0 
TMEM65 6,59 6,94 6,52 0 0 0 
PTP4A1/2 6,74 6,69 6,72 0 0 0 
HSPE1-
MOB4;MOB4 6,76 6,77 6,60 0 0 0 
LPPR1 6,96 6,49 6,54 0 0 0 
MTOR 6,72 6,59 6,80 0 0 0 
IMPAD1 6,68 6,70 6,73 0 0 0 
BACH2 6,27 7,03 6,36 0 0 0 
LSM4 6,74 6,69 6,58 0 0 0 
REM2 6,60 6,71 6,69 0 0 0 
VPS11 6,65 6,72 6,63 0 0 0 
KIAA1279 6,72 6,50 6,74 0 0 0 
ASAP1 6,60 6,62 6,73 0 0 0 
LUC7L 6,65 6,65 6,66 0 0 0 
ARHGAP32 6,67 6,71 6,57 0 0 0 
RAP2A/B/C 6,61 6,61 6,61 0 0 0 
POU3F1/2/3 6,69 6,50 6,59 0 0 0 
PAK7 6,50 6,76 6,46 0 0 0 
KALRN 6,53 6,62 6,58 0 0 0 
PIK3C2B 6,59 6,63 6,51 0 0 0 
INTS1 6,49 6,51 6,69 0 0 0 
MAVS 6,68 6,39 6,60 0 0 0 
GMPPB 6,64 6,64 6,37 0 0 0 
RABL6 6,48 6,61 6,56 0 0 0 
EIF3K 6,56 6,55 6,55 0 0 0 
CA2 6,48 6,42 6,70 0 0 0 
CELSR3 6,49 6,56 6,54 0 0 0 
EXOC3 6,50 6,57 6,51 0 0 0 
WDR7 6,52 6,59 6,43 0 0 0 
CEP97 6,55 6,51 6,48 0 0 0 
NDUFA12 6,56 6,55 6,40 0 0 0 
CBX1 6,44 6,50 6,55 0 0 0 
RPRD2 6,52 6,43 6,49 0 0 0 
NACAD 6,51 6,45 6,48 0 0 0 
TRAF6 6,51 6,40 6,50 0 0 0 
ACSS2 6,61 6,39 6,39 0 0 0 
IK 6,37 6,54 6,49 0 0 0 
STAU2 6,50 6,53 6,37 0 0 0 
ARVCF 6,48 6,54 6,38 0 0 0 
STAMBP 6,44 6,49 6,46 0 0 0 
AIDA 6,46 6,44 6,43 0 0 0 
HSPA14 6,38 6,44 6,50 0 0 0 
TIGD4;APBB1 6,44 6,42 6,44 0 0 0 
CNOT10 6,40 6,46 6,44 0 0 0 
NARS2 6,46 6,43 6,41 0 0 0 
INPP5F 6,36 6,36 6,50 0 0 0 
SLC35A4 6,38 6,43 6,43 0 0 0 
CHERP 6,40 6,41 6,38 0 0 0 
C10orf76 6,40 6,45 6,32 0 0 0 
AMER2 6,50 6,30 6,31 0 0 0 
FAM188A 6,54 6,24 6,29 0 0 0 
ARFIP2 6,29 6,43 6,40 0 0 0 
PPP1R12A 6,35 6,37 6,40 0 0 0 
FMR1 6,46 6,20 6,40 0 0 0 
MRE11A 6,35 6,26 6,45 0 0 0 
TRAPPC1 6,39 6,40 6,27 0 0 0 
POGLUT1 6,33 6,30 6,41 0 0 0 
DCK 6,26 6,54 6,15 0 0 0 
GABBR1 6,32 6,44 6,26 0 0 0 
TTYH1 6,27 6,19 6,51 0 0 0 
PML 6,28 6,17 6,51 0 0 0 
EXOC6B 6,45 6,28 6,26 0 0 0 
CNTNAP5 6,29 6,32 6,36 0 0 0 
DIS3L2 6,42 6,23 6,18 0 0 0 
CRBN 6,33 6,24 6,19 0 0 0 
FYTTD1 6,26 6,35 6,10 0 0 0 
DNAJB1 6,30 6,24 6,18 0 0 0 
NPC1 6,19 6,15 6,32 0 0 0 
TRAPPC9 6,12 6,28 6,13 0 0 0 
METTL13 6,27 6,14 6,11 0 0 0 
GEMIN5 6,17 6,11 6,21 0 0 0 
ACTBL2 9,07 0 7,39 0 0 0 
SRSF7 0 7,10 7,10 0 0 0 
PCNT 7,13 7,03 0 0 0 0 
TMEM35 7,08 0 6,96 0 0 0 
ATR 0 6,99 6,98 0 0 0 
KIAA1211 7,03 0 6,88 0 0 0 
RPL29 6,88 0 7,02 0 0 0 
NUDT1 0 7,05 6,80 0 0 0 
FAF1 6,93 6,86 0 0 0 0 
THG1L 7,04 0 6,68 0 0 0 
RPS15A 6,84 6,88 0 0 0 0 
NKIRAS2 0 6,91 6,75 0 0 0 
PFDN2 6,88 0 6,79 0 0 0 
COX5B 6,68 6,89 0 0 0 0 
ERCC4 6,73 6,81 0 0 0 0 
DNAJC7 6,68 0 6,77 0 0 0 
RAP1GAP 6,42 6,88 0 0 0 0 
COX5A 6,69 0 6,72 0 0 0 
SREK1 0 6,64 6,72 0 0 0 
CLVS1 6,83 6,44 0 0 0 0 
DAZAP1 0 6,65 6,69 0 0 0 
RASAL2 6,58 6,73 0 0 0 0 
DHX38 6,56 6,73 0 0 0 0 
KCTD15 6,72 0 6,56 0 0 0 
SORBS2 6,72 0 6,54 0 0 0 
TAB1 6,60 0 6,66 0 0 0 
SMAP2 6,66 6,59 0 0 0 0 
NR1I2 6,75 0 6,43 0 0 0 
GNB4 0 6,79 6,31 0 0 0 
SCAPER 6,64 6,59 0 0 0 0 
FOXP2 6,76 6,37 0 0 0 0 
EPHB1 0 6,68 6,52 0 0 0 
PREPL 6,46 6,67 0 0 0 0 
CLPB 0 6,60 6,56 0 0 0 
SIRPA 0 6,62 6,48 0 0 0 
UQCRQ 6,51 0 6,60 0 0 0 
RABL2A/B 6,51 6,60 0 0 0 0 
RABGEF1 6,54 6,54 0 0 0 0 
QTRTD1 6,41 0 6,63 0 0 0 
KIAA0930 6,55 0 6,50 0 0 0 
AKT3 6,51 0 6,53 0 0 0 
SKIV2L 6,42 0 6,60 0 0 0 
PPIL4 0 6,52 6,49 0 0 0 
RAD23A 6,53 0 6,45 0 0 0 
EFNB2 6,53 6,44 0 0 0 0 
ZYG11B 6,51 6,46 0 0 0 0 
ERI3 6,48 6,49 0 0 0 0 
CEND1 6,47 0 6,47 0 0 0 
NME7 6,53 6,39 0 0 0 0 
SELENBP1 6,58 0 6,29 0 0 0 
DIAPH1 6,46 6,45 0 0 0 0 
TRMT10C 0 6,44 6,45 0 0 0 
TMEM163 6,42 0 6,46 0 0 0 
KATNAL1 0 6,32 6,53 0 0 0 
DDX39A 0 6,32 6,52 0 0 0 
DTX3 6,46 6,40 0 0 0 0 
VCPIP1 6,38 6,46 0 0 0 0 
DCHS1 6,44 0 6,39 0 0 0 
ARMC1 0 6,44 6,36 0 0 0 
NDN 0 6,45 6,34 0 0 0 
UBR7 0 6,32 6,47 0 0 0 
BCS1L 0 6,50 6,26 0 0 0 
FECH 6,47 0 6,26 0 0 0 
GCLC 6,24 0 6,43 0 0 0 
QTRT1 0 6,43 6,22 0 0 0 
NAA30 6,25 6,40 0 0 0 0 
SMG8 6,29 6,36 0 0 0 0 
CHCHD6 0 6,44 6,15 0 0 0 
EIF2B2 6,34 0 6,30 0 0 0 
PCID2 0 6,23 6,39 0 0 0 
MYCBP2 6,28 6,34 0 0 0 0 
SLC25A29 6,27 6,33 0 0 0 0 
NCOA5 6,20 6,34 0 0 0 0 
CBWD1/2/3/5/6/7 6,17 6,36 0 0 0 0 
RDH14 0 6,45 5,97 0 0 0 
RPS6KA4/5 6,24 6,29 0 0 0 0 
PRPF4 6,28 6,24 0 0 0 0 
APPL2 6,19 0 6,31 0 0 0 
ERCC2 6,29 0 6,21 0 0 0 
ELP3 6,21 6,28 0 0 0 0 
NAGLU 6,25 6,20 0 0 0 0 
ZFYVE20 6,28 0 6,15 0 0 0 
KIAA1033 6,01 6,35 0 0 0 0 
GAK 0 6,33 6,03 0 0 0 
CDH10 6,29 0 6,08 0 0 0 
C18orf8 6,21 0 6,19 0 0 0 
DOCK3 6,06 6,28 0 0 0 0 
CCNY;CCNYL1/2 6,11 0 6,17 0 0 0 
IP6K1 6,08 6,14 0 0 0 0 
CAND2 0 6,06 6,11 0 0 0 
LZTS1 5,97 6,17 0 0 0 0 
 
Suppl. Table S4 | Proteins expressed in at least 2 patient CNs and no control CNs. Values are given in Log10 
LFQ intensity.  
Protein name CO4 CO5 CO6 STUB1_1 
STU
B1_2 
STU
B1_3 
VPS18 0 0 0 6,04 6,06 6,13 
SUPV3L1 0 0 0 6,23 6,09 6,07 
CPT1C 0 0 0 6,24 6,14 6,17 
PTPRO 0 0 0 6,21 6,20 6,18 
TARBP2 0 0 0 6,19 6,16 6,25 
ADAM10 0 0 0 6,37 6,12 6,06 
PRPS2 0 0 0 6,25 6,13 6,23 
PIGU 0 0 0 6,43 6,06 6,02 
WDR26 0 0 0 6,27 6,18 6,29 
DHX16 0 0 0 6,26 6,20 6,32 
NUDCD2 0 0 0 6,18 6,35 6,27 
STAM2 0 0 0 6,25 6,32 6,28 
USP48 0 0 0 6,25 6,29 6,34 
FBXO21 0 0 0 6,21 6,33 6,38 
MRPS9 0 0 0 6,46 6,20 6,24 
CNTN2 0 0 0 6,39 6,41 6,11 
TRAF2 0 0 0 6,32 6,37 6,31 
THNSL1 0 0 0 6,35 6,32 6,34 
FAHD2A/B 0 0 0 6,42 6,29 6,29 
SMYD3 0 0 0 6,31 6,17 6,50 
Mar-05 0 0 0 6,45 6,26 6,31 
CHTOP 0 0 0 6,28 6,39 6,40 
UROD 0 0 0 6,45 6,28 6,33 
FAR1 0 0 0 6,51 6,23 6,31 
DTNA;DTNB 0 0 0 6,52 6,27 6,28 
KDM3B 0 0 0 6,42 6,46 6,20 
TRAPPC4 0 0 0 6,37 6,42 6,36 
ZC3HC1 0 0 0 6,43 6,40 6,32 
TOM1L2 0 0 0 6,37 6,34 6,44 
MOCS3 0 0 0 6,31 6,45 6,40 
MID1 0 0 0 6,66 6,21 6,15 
PITPNM1 0 0 0 6,46 6,31 6,45 
RELA 0 0 0 6,41 6,43 6,41 
SNRPG;SNRPGP15 0 0 0 6,42 6,39 6,44 
CNOT2 0 0 0 6,37 6,44 6,44 
SLC8A2 0 0 0 6,15 6,58 6,44 
ALG9 0 0 0 6,55 6,37 6,33 
SRPK2 0 0 0 6,36 6,44 6,49 
ACSL1 0 0 0 6,54 6,38 6,36 
FAM120B 0 0 0 6,44 6,46 6,41 
PTCD3 0 0 0 6,58 6,38 6,30 
WASF3 0 0 0 6,23 6,59 6,48 
RSRC2 0 0 0 6,41 6,60 6,36 
PUM2 0 0 0 6,36 6,59 6,44 
GMPPA 0 0 0 6,56 6,42 6,45 
HMOX2 0 0 0 6,55 6,42 6,50 
YARS2 0 0 0 6,64 6,38 6,41 
SUMF2 0 0 0 6,63 6,41 6,41 
DNAJC9 0 0 0 6,60 6,45 6,44 
UBE4A 0 0 0 6,46 6,49 6,55 
NPC2 0 0 0 6,72 6,34 6,34 
TUBGCP2 0 0 0 6,48 6,50 6,54 
CYTH1/2/3 0 0 0 6,47 6,57 6,49 
CRAT 0 0 0 6,47 6,51 6,55 
C8orf82 0 0 0 6,65 6,45 6,40 
PFDN4 0 0 0 6,45 6,56 6,54 
NOSIP 0 0 0 6,60 6,48 6,47 
CNOT11 0 0 0 6,56 6,56 6,46 
TMEM11 0 0 0 6,59 6,54 6,44 
PACSIN2 0 0 0 6,54 6,48 6,57 
ANKRD28 0 0 0 6,30 6,71 6,49 
SPTLC1 0 0 0 6,77 6,30 6,39 
CYFIP1 0 0 0 6,53 6,47 6,59 
RALB 0 0 0 6,51 6,57 6,56 
CHID1 0 0 0 6,69 6,45 6,46 
ESYT2 0 0 0 6,72 6,41 6,46 
C11orf73 0 0 0 6,40 6,46 6,75 
CARS2 0 0 0 6,67 6,40 6,60 
IGF1R 0 0 0 6,75 6,48 6,40 
SELT 0 0 0 6,59 6,57 6,59 
BLVRB 0 0 0 6,58 6,67 6,51 
SLC35F6 0 0 0 6,82 6,43 6,40 
NUP35 0 0 0 6,68 6,54 6,57 
TMOD3 0 0 0 6,81 6,42 6,46 
ABI1 0 0 0 6,52 6,68 6,59 
LIG3 0 0 0 6,65 6,62 6,55 
MAP7D1 0 0 0 6,51 6,67 6,63 
TMEM256 0 0 0 6,78 6,49 6,48 
HRSP12 0 0 0 6,73 6,54 6,54 
NME4 0 0 0 6,93 6,36 6,16 
DST 0 0 0 6,69 6,60 6,54 
DVL2/3 0 0 0 6,69 6,56 6,60 
CDK9 0 0 0 6,66 6,58 6,63 
FAM171A2 0 0 0 6,54 6,69 6,65 
DDI2 0 0 0 6,81 6,49 6,52 
UBXN6 0 0 0 6,58 6,67 6,65 
AP3B1 0 0 0 6,91 6,42 6,35 
COLGALT1 0 0 0 6,92 6,36 6,40 
SNX3 0 0 0 6,69 6,59 6,68 
HPCAL4 0 0 0 6,47 6,78 6,69 
TRAPPC3 0 0 0 6,57 6,67 6,74 
C4orf27 0 0 0 6,63 6,67 6,72 
AVIL 0 0 0 6,59 6,76 6,66 
MOB1A/B 0 0 0 6,94 6,51 6,42 
STK4 0 0 0 6,69 6,64 6,73 
RBBP7 0 0 0 6,58 6,53 6,88 
DENR 0 0 0 6,66 6,77 6,65 
WRNIP1 0 0 0 6,65 6,63 6,80 
TMCO1 0 0 0 6,74 6,71 6,67 
PPP1R8 0 0 0 6,69 6,70 6,75 
GOLGA4 0 0 0 6,60 6,62 6,89 
LRPAP1 0 0 0 6,99 6,53 6,44 
M6PR 0 0 0 6,80 6,66 6,74 
SERINC1 0 0 0 6,86 6,68 6,65 
TIGAR 0 0 0 6,77 6,70 6,76 
RER1 0 0 0 6,93 6,62 6,61 
PCYOX1L 0 0 0 6,71 6,77 6,78 
GPC6 0 0 0 6,98 6,56 6,59 
TIMM23;TIMM23B 0 0 0 6,73 6,79 6,78 
PSEN1/2 0 0 0 6,95 6,68 6,66 
MBOAT7 0 0 0 6,94 6,70 6,67 
PPAPDC2 0 0 0 6,69 6,93 6,72 
SYNE1 0 0 0 6,88 6,72 6,76 
PEX11B 0 0 0 6,88 6,77 6,79 
PHPT1 0 0 0 6,79 6,81 6,87 
CARHSP1 0 0 0 6,84 6,86 6,85 
NDUFS7 0 0 0 6,97 6,80 6,81 
BDH2 0 0 0 6,92 6,85 6,83 
PDPK1/2 0 0 0 6,76 6,99 6,83 
REEP5 0 0 0 6,96 6,84 6,81 
ITGB1 0 0 0 7,22 6,62 6,56 
UNC119B 0 0 0 6,93 6,84 6,97 
MMAB 0 0 0 7,11 6,94 6,73 
NELFA 0 0 0 6,77 7,05 7,01 
POFUT1 0 0 0 7,23 6,71 6,74 
CISD2 0 0 0 6,95 6,91 7,03 
RBM8A 0 0 0 6,97 7,01 6,96 
C21orf33 0 0 0 7,06 7,05 7,06 
SSR4 0 0 0 7,23 7,02 6,91 
SEC61B 0 0 0 7,17 7,09 6,99 
ARSB 0 0 0 7,32 6,94 7,03 
PAPSS1 0 0 0 7,33 7,11 7,05 
NR2F1 0 0 0 7,70 7,20 6,85 
RTN1 0 0 0 7,31 7,67 7,53 
LMNA 0 0 0 8,02 6,58 6,39 
ACTB 0 0 0 8,12 8,18 8,14 
MRPS34 0 0 0 0 6,08 6,01 
KATNB1 0 0 0 5,99 0 6,12 
PI4K2A 0 0 0 6,23 5,79 0 
C7orf26 0 0 0 6,10 6,11 0 
PICK1 0 0 0 0 6,10 6,17 
NDC1 0 0 0 6,24 0 6,21 
EFHD1/2 0 0 0 0 6,33 6,11 
FOXRED1 0 0 0 6,26 6,21 0 
IQSEC1 0 0 0 6,11 6,36 0 
UBE4B 0 0 0 0 6,16 6,34 
MPP6 0 0 0 6,17 6,34 0 
PTPRD 0 0 0 0 6,29 6,23 
TMEM68 0 0 0 6,35 6,18 0 
RBM17 0 0 0 6,29 0 6,27 
EI24 0 0 0 6,28 6,31 0 
PLCD1 0 0 0 6,37 0 6,21 
TPD52L2 0 0 0 6,43 0 6,18 
GTF3C5 0 0 0 6,36 6,28 0 
ARMC10 0 0 0 6,35 6,31 0 
AASS 0 0 0 6,46 6,18 0 
TAOK1 0 0 0 0 6,39 6,36 
EXOSC7 0 0 0 6,35 0 6,40 
RFX3 0 0 0 6,28 6,45 0 
PEX14 0 0 0 6,34 0 6,42 
MRPL48 0 0 0 6,52 6,21 0 
ABCF2 0 0 0 6,49 6,29 0 
MYT1 0 0 0 0 6,32 6,47 
TRMT1;SEMA4B 0 0 0 6,49 0 6,30 
AGL 0 0 0 0 6,50 6,30 
H6PD 0 0 0 6,50 0 6,31 
RNF214 0 0 0 0 6,43 6,40 
GMPR2 0 0 0 6,27 0 6,53 
DAGLB 0 0 0 6,61 0 6,08 
ARRB2 0 0 0 0 6,46 6,39 
MRPL4 0 0 0 6,49 6,36 0 
EIF4G3 0 0 0 6,44 0 6,42 
ARHGAP21 0 0 0 0 6,42 6,45 
MTPAP 0 0 0 6,60 0 6,19 
NUBP2 0 0 0 6,33 0 6,53 
CPOX 0 0 0 6,46 0 6,43 
RAB3B 0 0 0 6,55 6,32 0 
MPI 0 0 0 6,36 0 6,55 
TMEM214 0 0 0 6,67 0 6,06 
RMDN1 0 0 0 6,56 0 6,37 
HIBADH 0 0 0 6,67 6,12 0 
SEH1L 0 0 0 6,57 6,36 0 
MRPL43 0 0 0 0 6,44 6,51 
NOL4L 0 0 0 0 6,43 6,52 
PJA2 0 0 0 6,54 6,42 0 
CELF4 0 0 0 0 6,45 6,51 
ERLIN1 0 0 0 6,62 0 6,30 
DNMT1 0 0 0 6,59 0 6,40 
TSPAN6 0 0 0 6,69 0 6,21 
SGSH 0 0 0 6,69 6,22 0 
RAP1A/B 0 0 0 6,49 0 6,57 
FDXR 0 0 0 6,70 6,29 0 
CHL1 0 0 0 6,71 6,32 0 
MACROD2 0 0 0 0 6,55 6,60 
GUCY1B3 0 0 0 0 6,52 6,64 
SPCS1 0 0 0 0 6,62 6,59 
TMEM30A 0 0 0 0 6,70 6,51 
PPP4R1 0 0 0 0 6,59 6,68 
EIF2B5 0 0 0 6,58 0 6,69 
RPS15 0 0 0 0 6,72 6,56 
CCDC132 0 0 0 0 6,62 6,67 
PRNP 0 0 0 0 6,62 6,71 
PLOD3 0 0 0 6,88 6,22 0 
RAB33A 0 0 0 0 6,72 6,64 
TOMM20 0 0 0 0 6,77 6,58 
ITGAV 0 0 0 6,90 0 6,28 
SF3B4 0 0 0 6,68 0 6,73 
CTSA 0 0 0 6,84 6,59 0 
CPVL 0 0 0 6,92 0 6,47 
RBX1 0 0 0 0 6,83 6,67 
FAT1 0 0 0 6,92 0 6,55 
EIF1;EIF1B 0 0 0 6,78 6,77 0 
BTF3L4 0 0 0 6,73 6,82 0 
PVRL2 0 0 0 6,97 0 6,50 
BSCL2 0 0 0 6,90 6,67 0 
VPS52 0 0 0 6,83 0 6,91 
EPHA7 0 0 0 7,05 6,69 0 
GPM6B 0 0 0 6,87 7,12 0 
SCGN 0 0 0 0 6,60 7,28 
MGST1 0 0 0 7,30 0 6,75 
DBI 0 0 0 0 7,12 7,14 
PDPR 0 0 0 0 7,07 7,19 
UBTF 0 0 0 7,19 0 7,22 
P4HA1 0 0 0 7,50 6,28 0 
TP53I11 0 0 0 0 7,41 7,09 
SWAP70 0 0 0 7,46 7,29 0 
CALB1 0 0 0 7,80 6,78 0 
TTN 0 0 0 7,99 8,04 0 
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Human skin fibroblasts were isolated from a 40-year-old hereditary spastic paraplegia patient carrying an
intronic splice site mutation (c.1687 + 2 T N A) in SPAST, leading to hereditary spastic paraplegia type 4
(SPG4). Fibroblasts were reprogrammed using episomal plasmids carrying hOCT4, hSOX2, hKLF4, hL-MYC and
hLIN28. The generated transgene-free line iPS-SPG4-splice retained the specific mutation with no additional ge-
nomic aberrations, expressed pluripotency markers and was able to differentiate into cells of all germ layers in
vitro. The generated iPS-SPG4-splice line might be a useful platform to study the pathomechanism of SPG4.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Origin Human skin fibroblasts
Type of resource Biological reagent: induced pluripotent stem cell (iPSCs);
derived from a SPG4 patient carrying a heterozygous
c.1687 + 2 T N A splice site mutation
Sub-type Induced pluripotent stem cells (iPSCs)
Key transcription
factors
hOCT4, hSOX2, hKLF4, hL-MYC, hLIN28 (Addgene plasmids
27,076, 27,078 and 27,080; Okita et al., 2011)
Authentication Identity and purity of iPS-SPG4-splice line confirmed by
analysis of plasmid integration, mutation sequencing, SNP
array analysis, pluripotency markers and in vitro
differentiation potential
Link to related
literature
N/A
Information in public N/A
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Name of Stem Cell
line iPS-SPG4-splice
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Ethics Patient informed consent obtained/ Ethics Review
Board-competent authority approval obtained
1. Resource details
Hereditary spastic paraplegia (HSP) is a neurodegenerative disorder
characterised by lower limb spasticity and weakness due to axonal de-
generation in the corticospinal tract. The most common form of HSP is
the autosomal dominantly inherited spastic paraplegia type 4 (SPG4)
which is caused by mutations within the SPAST gene encoding for the
microtubule-severing enzyme spastin (Schule et al., 2016). To study
the underlying disease mechanisms, the iPSC line iPS-SPG4-splice was
generated by delivery of episomal plasmids encoding human OCT4,
SOX2, KLF4, L-MYC and LIN28 in skin fibroblasts from a 40-year-old pa-
tient with a phenotype of pure HSP (Okita et al., 2011). Gait difficulties
developed early in childhood with a slowly progressive course of dis-
ease. The quality of the generated iPSCs was investigated by genotypic
and functional assays. Genomic integrity was analysed by comparative
SNP analysis of fibroblasts and the generated iPSCs (Fig. 1A),
resequencing of themutation-site (Fig. 1B) andexclusion of genomic in-
tegration of episomal plasmids (Fig. 1C). The expression of pluripotency
markers on protein and RNA levelwas assessed by alkaline phosphatase
staining (ALP) (Fig. 2A), immunocytochemical stainings of OCT4, TRA-
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1-81, NANOG and SSEA-4 (Fig. 2B) as well as qRT-PCR analysis of OCT4,
NANOG, KLF4, c-MYC, SOX2, REX1, DNMT3B and TDGF1 in comparison
to human embryonic stem cell lines (HuES-H6 / HuES\\H9) and fibro-
blasts (Fig. 2C). Additionally, the potential of generated iPSCs to differ-
entiate into cells of all three germ layers was investigated. iPSCs were
able to differentiate into neurons expressing β-III-tubulin, muscle cells
positive for α-smooth muscle actin (SMA), and early endodermal cells
positive for α-fetoprotein (AFP) (Fig. 2D).
2. Materials andmethods
2.1. Reprogramming of fibroblast to iPSCs
Patient fibroblasts carrying a heterozygous splice site mutation
(c.1687 + 2 T N A) in SPAST were derived from skin biopsies by
dissection and cultivation infibroblast medium consisting of Dulbecco's
modified eagle's medium (DMEM) high glucose (Life technologies)
with 10% fetal bovine serum (FBS, Life technologies). After approx.
10 days of cultivation at 37 °C and 5% CO2 fibroblasts were collected
and expanded by medium change every 2–3 days. Reprogramming
was achieved by nucleofection of 1× 105 cells with 1 μg of each plasmid
(hOCT4, hSOX2, hKLF4, hL-MYC and hLIN28 (Okita et al., 2011)) using the
Nucleofector 2D system (Lonza). After reprogramming, cells were re-
placed in onewell of a 6-well plate and cultivated for 1 day in fibroblast
medium. After a period of 2 days in fibroblast medium supplemented
with 2 ng/ml FGF-2 (Peprotech) cells were transferred to Essential 8
(E8) medium containing 100 μM NaB (Sigma-Aldrich). 3–4 weeks
after reprogramming, iPSC colonies were picked manually and further
cultivated on Matrigel-coated 6-well dishes using E8 medium. IPSCs
were split in a ratio of 1:6–1:12 by adding PBS/EDTA (0.02% EDTA in
Fig. 1. Genomic characterisation of generated iPS-SPG4-splice. (A) SNP array analysis of fibroblast (F-SPG4-splice) and generated iPSCs (iPS-SPG4-splice) reveal genomic integrity. Data is
shown in whole genome view (WGV) and expressed as the weighted log2 ratio of the copy number on the left Y-axis (blue line), and the chromosome number on the X-axis. (B) Sanger
sequencing of the region containing the heterozygous splice site mutation c.1687 + 2 T N A in F-SPG4-splice and iPS-SPG4-splice. (C) RT-PCR verification of the absence of plasmid
integration in iPS-SPG4-splice. Plasmid-specific primer for hOCT3/4, SOX2, KLF4, and L-MYC with DNA from iPS-SPG4-splice, plasmid samples as positive control, and ddH2O as
negative control were used.
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PBS). Between passage 5 and 10, cells were analysed and frozen in E8
mediumwith 40% KOSR (Life technologies), 10%DMSO (Sigma-Aldrich)
and 1 μM Y-27632 (Abcam Biochemicals).
2.2. SNP array analysis
DNA was isolated using the DNeasy blood & tissue kit (Qiagen) ac-
cording to themanufacturer's guidelines.Using theAffymetrix CytoScan
HD technology (Affymetrix) SNP array analysis was performed by using
2 μg of DNA of the iPSC line as well as the original fibroblast line. Raw
data was processed using Affymetrix Chromsome Analysis Suite
(ChAS) 2.0 software.
2.3. Sequencing of mutation site
Using the 3130xlGenetic Analyzer (Applied Biosystems) and aprim-
er set flanking the mutation (c.1687 + 2 T N A) in SPAST, the mutation
site was analysed by applying standard procedures and visualization
with Staden 2.0.0b10 software (Staden Sourceforge).
Fig. 2. Functional characterisation of generated iPS-SPG4-splice by (A) alkaline phosphatase (ALP) activity and the expression of specific pluripotency marker identified via (B)
immunocytochemical staining of OCT4 (green), TRA1–81 (red) as well as NANOG (green) and SSEA-4 (red). Nuclei are counterstained with DAPI (blue). Scale bar = 50 μm. (C) qRT-
PCR with cDNA from iPS-SPG4-splice, HuES\\H6, HuES-H9 and fibroblasts and pluripotency specific primers OCT4, NANOG, KLF4, C-MYC, SOX2, REX1, DNMT3B and TDGF1 normalized
to the housekeeping gene GAPDH and the hESCs HuES\\H6. (D) Immunostainings of ectodermal (β-III-tubulin (TUJ), scale bar = 100 μm), endodermal (α-fetoprotein (AFP), scale
bar = 50 μm) and mesodermal (α-smooth-muscle-actin (SMA), scale bar =50 μm) markers reveal the differentiation potential of iPS-SPG4-splice. Nuclei are counterstained with
DAPI (blue).
Table 1
Primers (Okita et al., 2011) used for integration analysis by PCR.
Forward sequence Reverse sequence
KLF4 CCACCTCGCCTTACACATGAAG TAGCGTAAAAGGAGCAACATAG
L-MYC GGCTGAGAAGAGGATGGCTAC TTTGTTTGACAGGAGCGACAAT
OCT3/4 CATTCAAACTGAGGTAAGGG TAGCGTAAAAGGAGCAACATAG
SOX2 TTCACATGTCCCAGCACTACCAG TTTGTTTGACAGGAGCGACAAT
Table 2
Primers used for validation of pluripotency genes.
Forward sequence Reverse sequence
c-MYC ATTCTCTGCTCTCCTCGACG CTGTGAGGAGGTTTGCTGTG
DNMT3 ACGACACAGAGGACACACAT AAGCCCTTGATCTTTCCCCA
GAPDH AGGTCGGAGTCAACGGATTT ATCTCGCTCCTGGAAGATGG
KLF4 CCATCTTTCTCCACGTTCGC CGTTGAACTCCTCGGTCTCT
NANOG CAAAGGCAAACAACCCACTT TGCGTCACACCATTGCTATT
OCT4 GGAAGGTATTCAGCCAAACG CTCCAGGTTGCCTCTCACTC
REX1 AACGGGCAAAGACAAGACAC AACTCACCCCTTATGACGCA
SOX2 TGATGGAGACGGAGCTGAAG GCTTGCTGATCTCCGAGTTG
TDGF1 GGTCTGTGCCCCATGACA AGTTCTGGAGTCCTGGAAGC
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2.4. Non-integration of transgenes
DNA was isolated as described before. Using plasmid specific
primers (see Table 1) as well as the three episomal plasmids (pCXLE-
hUL, pCXLE-hSK and pCXLE-hOCT4) as positive control the integration
was analysed. Therefore, RT-PCR reactions were performed using
GoTaq G2 DNA Polymerase (Promega) according to the manufacturer's
instruction. PCR products were separated on a 2.0% agarose gel and vi-
sualized with Midori Green.
2.5. Alkaline phosphatase staining
For ALP staining iPSCswere cultivated on 12-well plates and fixed in
4% paraformaldehyde (PFA) for 1 minute. After 3 times washing in PBS
staining solution (40 μl Naphthol AS-MX phosphate alkaline solution
(Sigma-Aldrich) and 1 ml Fast Red (1 mg/ml, Sigma Aldrich)) was
added for 30 min. ALP-positive colonies were stained dark red.
2.6. Immunocytochemical staining
iPSCs were cultivated on 24-well plates on coverslips until
confluency of 60–80%. After fixation in 4% paraformaldehyde (PFA) for
15 min cells were washed 3 times with PBS and incubated in blocking
buffer (PBS, 1% FCS, 0.1% Triton X-100) for 45 min. Cells were stained
for 1 h at room temperature (RT) with the primary antibody (see
Table 3). After 3washes in PBS, cells were incubatedwith the secondary
antibody (Alexa488 or Alexa568 diluted 1:300 (Life technologies)) in
the dark at RT for 1 h. Nuclear counterstainingwas achieved by addition
of DAPI (1:10,000) for 15min at RT in the dark. After embedding in Pro-
LongDiamondAntifadeMountant cellswere analysedwithAxio Imager
Z1 with ApoTome (Zeiss).
2.7. qRT-PCR of pluripotency marker
RNA was isolated using the High Pure RNA Isolation Kit (Roche) ac-
cording to the manufacturer's guidelines. Reverse transcription was
performed using the Transcriptor High Fidelity cDNA Synthesis Kit
(Roche). Using Light Cycler 480 SYBR Green I Master (Roche) and spe-
cific pluripotency gene primers (see Table 2) qRT-PCR was performed.
Runs were performed as triplicates and CT-values were normalized
using the 2-ΔΔCt method with the hESC line HuES-H6 as reference and
GAPDH as housekeeping gene.
2.8. In vitro differentiation potential
For embryonic body (EB) generation iPSCswere cultivated in EBme-
dium consisting of 80% DMEM/F12 (Life technologies), 20% KOSR, 1×
NEAA, 1× Pen/Strep, 2 mM L-Glutamine and 0.1 mM 2-
Mercaptoethanol on AggreWell 800 plates (Stemcell Technologies)
with medium change at day 2. EBs were collected on day 4 and plated
on 0.1% gelatine (Sigma-Aldrich) coated coverslips. Cells were cultivat-
ed for additional 2–3 weeks with medium change every other day and
analysed by immunocytochemical staining using antibodies against
AFP (α-fetoprotein), SMA (α-smoothmuscle actin) andTUJ (β-III-tubu-
lin) (see Table 3).
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Abstract  
Disease modelling requires appropriate cellular models that best mimic the underlying 
pathophysiology. Human origin and an adequate expression of the disease protein are pre-
requisites that support information from a model to be meaningful. In this study we investigated 
expression profiles of (i) PBMCs and (ii) fibroblasts as patient derived cells as well as (iii) 
lymphoblasts and (iv) induced pluripotent stem cells (iPSC) as immortalized sources and (v) iPSC-
derived cortical neurons to assess its aptitude to model motor neuron diseases (MNDs) including 
hereditary spastic paraplegia (HSP), amyotrophic lateral sclerosis (ALS) and spinal muscular 
atrophy (SMA). We generated all five cell lines from two healthy donors and performed RNA 
sequencing to display expression patterns in MND-related genes. For the ten most common HSP 
genotypes we proved gene expression by qPCR. Depending on the specific MND gene we found 
largely different expression patterns. Out of 168 MND-related genes, 50 had their highest 
expression in iPSC-derived cortical neurons, 41 were most strongly expressed in fibroblasts, 26 in 
lymphoblasts, 22 in iPSCs and 14 in PBMCs. 15 MND-related genes were not detectable in any of 
the analyzed cell types. This study provides comprehensive information on expression of genes 
associated with a large spectrum of MNDs. Expression profiles can be used to inform on 
appropriate cell models for genotype specific motor neuron research.  
  
Introduction 
Studies on pathophysiology of human disease and the development of new therapeutics are 
essentially dependent on suitable disease models. This is particularly difficult in neurological 
disease as often only the nervous system is affected and access to human neuronal tissue is 
limited to nerve and brain biopsies or post-mortem material that are notoriously rare with very 
limited access. 
Primary patient cells like peripheral blood mononuclear cells (PBMCs) isolated from blood or 
fibroblasts isolated from skin biopsies are easily accessible but not primarily affected by the 
disease and therefore might represent pathophysiological processes only to a limited and often 
unknown extend. Additionally, primary patient cells possess limited growth capacity which 
hampers its use in large-scale screening approaches. To overcome this limitation strategies of 
immortalizing primary patient cells have been developed early on, e.g. the transformation of 
PBMCs (mainly B lymphocytes) to lymphoblasts by using the Epstein-Barr virus (Miller, 1982). 
With the discovery of induced pluripotent stem cells (iPSCs) a novel and promising technique to 
generate disease-relevant and patient-specific cell types arose (Takahashi and Yamanaka, 2006). 
Over the last years iPSCs became a widespread tool to generate neuronal cell types that are 
genetically identical with patients suffering from the neurological disease of interest. iPSCs can 
be reprogrammed from easily accessible cell types like fibroblasts, PBMCs or keratinocytes 
according to well standardized procedures (Okita et al., 2013; Hauser et al., 2016a). iPSC-derived 
neurons have been used to model many human neurological diseases including motor neuron 
diseases (MNDs).   
MNDs comprise three major groups of rare neurodegenerative diseases including (i) hereditary 
spastic paraplegia (HSP) involving primarily upper motor neurons, (ii) spinal muscular atrophy 
(SMA) with lower motor neuron affection and (iii) amyotrophic lateral sclerosis (ALS) with rapid 
degeneration of upper and lower motor neurons. All three MNDs are genetically highly 
heterogeneous and split up into more than 80 genotypes of HSP, at least 30 genes causing ALS 
and 18 genes associated with SMA (Adam et al.; Kinsley and Siddique, 2015; Hedera, 2018). 
Further, MNDs show a substantial overlap with other disease groups like cerebellar ataxias, 
leukoencephalopathies and hereditary peripheral neuropathies  (Synofzik and Schüle, 2017). In 
total more than 160 genes related to motor neuron impairment are known to date.  
Till the discovery of iPSCs, research on MND mostly focused on mouse models and cell culture 
models using immortalized murine and human cell lines. Animal models are advantageous in 
providing an in vivo system with its whole complexity but differences between species are huge 
and transferability to human disease is difficult. This is especially true in the context of 
neurological disorders. The hope that mouse models mimic human disease pathology has been 
disappointing in particular for MNDs (reviewed in Genc et al., 2019).   
The potential of iPSC to generate a patient-specific cell model that represents the cell type 
affected by the disease of interest opened new possibilities to study MND in a human neuronal 
cell culture model (reviewed in Denton et al., 2016). For example, analysis of SPAST-deficient 
neurons generated from SPG4 patients revealed pathophysiological axonal defects like axonal 
swellings, a hallmark of HSP disease pathology, in human iPSC-derived neurons (Havlicek et al., 
2013; Denton et al., 2014). Further, in a study of SPG5, iPSC-derived neurons were employed to 
decipher the neurotoxic role of oxysterols that is likely to drive pathogenesis in this subtype of 
HSP (Schöls et al., 2017). Additionally, iPSC-derived neurons have been used for pharmacological 
screens to identify novel targets for the treatment of MNDs e.g. in SPG4 and SPG11 (Pozner et 
al., 2018; Rehbach et al., 2019). iPSC-derived motor neurons and cortical neurons have also been 
used to mimic familial as well as sporadic forms of ALS. Observed phenotypes range from e.g. 
cytoskeletal defects, impaired axonal transport, cell death and vulnerability, ER stress and 
mitochondrial dysfunction (reviewed in: Guo et al., 2017).   
To choose an adequate disease model is of utmost importance for medical research. The 
expression of disease-related molecules is a pre-requisite of meaningful cell models. Using RNA-
Sequencing (RNA-Seq) analyses we here compared the transcript expression profiles of more 
than 160 MND-related genes including all spastic paraplegia genes (SPGs), SMA genes and ALS 
genes known so far in biosamples of two independent healthy individuals including (i) PBMCs and 
(ii) fibroblasts as primary cells, (iii) lymphoblasts and (iv) iPSCs as immortalized cell lines as well 
as (v) iPSC-derived cortical projection neurons representing a cell type predominantly affected in 
HSP and ALS. This dataset may help to inform about the ideal source of human cell culture to 
model the disease of interest.  
Results 
To analyze MND-related gene expression in different cell types of the same individual peripheral 
blood mononuclear cells (PBMC) as well as fibroblasts (F) from two healthy donors were isolated 
from whole blood and skin biopsies. An immortalized lymphoblast cell line (LB) was generated by 
infection of PBMCs using the Epstein-Barr-Virus (EBV). Fibroblast were reprogrammed to induced 
pluripotent stem cells (iPSCs) and further differentiated to cortical projection neurons (CN) (Fig. 
1A). By this, we were able to compare various cell types ranging from easily-accessible primary 
cells over immortalized cell lines to cell types affected by MNDs.    
By comparing the global RNA-Sequencing profile of the various cell types we found a highly 
different and cell type-specific gene expression profile (Fig. 1B). As expected PBMCs and 
lymphoblasts closely clustered together while the other analyzed cell types showed very 
divergent and unique global transcript profiles as shown by principal component analysis. Of 
interest, there was high similarity between the same cell types of different individuals. This is also 
represented by the expression of cell type-specific markers (Fig. 1C). PBMCs and lymphoblasts 
exclusively expressed the marker HLA-DRA (HLA class II histocompatibility antigen, DR alpha 
chain) and CD74 (HLA class II histocompatibility antigen gamma chain), while fibroblast could be 
discriminated by expression of ELN (elastin) and LOX (lysyl oxidase). Pluripotency markers like 
OCT4 (octamer-binding transcription factor 4) and LIN28 (lin-28 homolog A) were exclusively 
detectable in iPSCs, whereas MAP2 (microtubule-associated protein 2) and NSG2 (neuronal 
vesicle trafficking-associated protein 2) were highly expressed solely in iPSC-derived cortical 
neurons. This highlights the purity of our cell culture systems and supports the validity of this 
analysis.  
To compare the gene expression profile in the different cell types a list of 168 MND-related genes 
was generated. This list covered all hereditary spastic paraplegia genes (SPGs) known at the time 
of study including 65 HSP genes (SPG1 – SPG80; SPGs with defined chromosomal loci but 
unknown genes could not be analyzed), 30 ALS-related genes, 18 SMA-related genes and 55 
spasticity-related genes. To normalize for sequencing depth we divided the total reads per 
sample by 1,000,000 (RPM – reads per million) and further normalized for gene length by dividing 
the RPM values of each gene by the length of the gene in kilobases (RPKM – reads per kilobase 
million).  
A summary of all analyzed MND-related genes in an alphabetic order can be seen in figure 2. 
RPKM values ranged from 0 – 538 depending on cell type and gene of interest. For a better 
visualization genes with RPKMs > 105 were separately visualized (Fig. 2B). We observed high 
variability in gene expression between cell types of the same donor and low variability between 
the same cell type of different donors.   
For a clearer presentation and easier comparison of the different gene expression patterns the 
relative expression values for each gene and disease were determined. Therefore, the mean 
value of both donors per gene and cell type were calculated and the highest value of each gene 
was set to 100% (Fig. 3). Afterwards genes were classified per disease (HSP, ALS and SMA) and 
grouped according to its highest expression per cell type from high to low RPKMs.   
Out of 65 HSP-related genes, 26 had their highest expression in iPSC-derived cortical neurons 
ranging from 2 – 328 RPKMs. 2 were most strongly expressed in iPSCs (range: 21 – 294 RPKMs), 
19 in fibroblasts (range: 1 – 65 RPKMs), 10 in lymphoblasts (range: 6 – 63 RPKMs)  and 3 in PBMCs 
(range: 2 – 16 RPKMs). 5 of 65 HSP-related genes were not detectable in any of the analyzed cell 
types.  
Concerning the 30 ALS-causing genes, 9 were expressed highest in neurons (range: 4 – 90 RPKMs) 
whereas, 5 showed higher expression in iPSCs (range: 5 – 538 RPKMs), 5 in fibroblasts (range: 2 
– 148 RPKMs), 6 in lymphoblasts (range: 3 – 511 RPKMs) and 3 in PBMCs (range: 16 – 30 RPKMs). 
ANG and UBQLN2 were not detectable at all.    
Out of the 18 analysed SMA-related genes, 5 were most abundant in neurons (range: 4 – 62 
RPKMs), 2 in iPSCs (range: 2 – 5 RPKMs), 3 in fibroblasts (range: 2 – 41 RPKMs), 4 in lymphoblasts 
(range: 9 – 38 RPKMs), 1 in PBMCs (1 RPKM). 3 genes (AR, ATP7A and UBA1) were not detected 
in any of these cell types.  
To validate and replicate the results of the RNA-Seq analysis, the 10 most common HSP genes 
according to a large representative HSP cohort (Schüle et al. 2016) were selected for further qRT-
PCR determination and validation (Fig. 4). Two of these genes (KIF5A, SPG11) are also associated 
with ALS. In general, expression profiles were found to be largely similar in RNA-Seq data and 
qRT-PCR for SPG3 (ATL1), SPG4 (SPAST), SPG5 (CYP7B1), SPG7 (SPG7), SPG10 (KIF5A), SPG11 
(SPG11), SPG15 (ZFYVE26), SPG17 (BSCL2), SPG31 (REEP1) and SPG35 (FA2H) (Fig. 4B-K).  For 
example, REEP1 was almost exclusively expressed in iPSC-derived cortical neurons (CNs) while 
SPAST was approximately 10 times lower expressed in PBMCs, LBs, Fs and iPSCs compared to 
CNs. Again, a very low variability of qRT-PCR data was observed between the same cell types of 
two independent donors.  
 
Discussion 
This study presents a comparative data set of the expression of >160 MND-related genes in 
patient-derived primary biosamples (PBMCs and fibroblasts), immortalized cell lines 
(lymphoblasts, iPSCs) as well as cortical neurons reflecting the cell type affected by the disease. 
In general, the direct comparison of the expression data of two independent healthy individuals 
showed large similarity in expression profiles for a given cell type (e.g. fibroblasts) between 
individuals but a huge variability within the same individual across different cell types. Figures 2 
and 3 provide an overview on expression profiles to inform on suitable cell types that express the 
RNA of interest of >160 MND-related transcripts. Cells with highest expression are recommended 
for further studies to compare differences in protein expression between patients and controls 
and its pathophysiological relevance. 
The highest expression of MND-related genes varied largely between the five cell types on 
analysis in this study. 8.3% of MND genes were most abundant in PBMCs, 15.5% in lymphoblasts, 
24.4% in fibroblasts, 13.1% in iPSCs and 29.8% are expressed highest in CNs, while 8.9% of all 
MND-related genes could not be identified in any of the analyzed cell types. Comparable 
distributions could also be seen for all three groups of MND with CNs being the most commonly 
represented cell type (HSP: 40%, ALS: 30%, SMA: 28%). An overview of all HSP, SMA and ALS 
genes and the respective cell type with the highest expression is provided in figure 5. This clearly 
shows that a general statement of an ideal cell type for disease modelling of MNDs is not valid. 
Nevertheless, iPSC-derived cortical neurons and/or fibroblasts are in most cases more suitable 
cell types compared to PBMCs or lymphoblasts.   
We selected projection neurons of cortical layer V/VI for this study as they can be differentiated 
with high purity from iPSC and motor neurons constitute a specific subtype of projection neurons 
originating from cortical layer V/VI. Our differentiation protocol allowed for a reproducible 
generation of a largely homogeneous neuronal cell population with 100% of cells expressing ß-
III-tubulin as neuronal marker and >85% of cells being positive for CTIP-2 expression indicating 
cortical projection neurons of layer V/VI (Rehbach et al., 2019). This allows to perform RNA-Seq 
analysis of neurons without cross-contamination of cells of glial origin as demonstrated by the 
non-detection of glial markers like GFAP. Established motor neuron protocols do not reach such 
an extent of purity and represent lower (rather than upper) motor neurons that are not affected 
in HSP (reviewed in: Sances et al., 2016).   
The intuitive notion that the expression of MND genes is highest in cortical neurons as the 
primary affected cell type in HSP and ALS is only true in ~30% of all MND genes. This may reflect 
that the function of a motor neuron and especially its extremely long axons require additional 
functionality of supporting cells including oligodendrocytes, microglia, astrocytes as well as 
peripheral Schwann cells and is further influenced by more general systemic metabolic pathways 
and changes. In extreme cases, especially when gene products play a role in general metabolic 
pathways like ARSI (SPG66) or CYP27A1 (CTX), the expression of the RNA is absent in iPSC-derived 
cortical neurons but is highest in fibroblasts or PBMCs (Fig. 2 and Fig. 3). The other way round, 
more easily available patient-derived cell types like fibroblasts and PBMCs do not express several 
relevant MND genes like SPG10 (KIF5A), SPG26 (B4GALNT1), SPG31 (REEP1), ERBB4 and PLEKHG5 
and therefore disqualify as cellular models for pathogenic studies in these MNDs.   
Studying the expression profiles by looking at specific clusters that share a similar cellular 
function as summarized by Blackstone and colleagues (2018), some pathophysiologically related 
HSPs show similar expression profiles. HSPs associated with axonal transport deficits like SPG4 
(SPAST), SPG10 (KIF5A), SPG30 (KIF1A), SPG31 (REEP1) and SPG72 (REEP2) share highest 
expression in cortical neurons as their primary side of action and are only low expressed or absent 
in all other analyzed cell types. Interestingly, some RNAs including L1CAM (SPG1), PLP1 (SPG2), 
MAG (SPG75) and GFAP (Alexander disease) are expressed in none of the cell types studied here. 
These genes define subtypes of MNDs with primary myelin or glial dysfunction. For example PLP1 
(proteolipid protein) is the primary constituent of myelin in the central nervous system (Diehl et 
al., 1986). In this specific subset of MND-related genes a suitable cell culture model probably 
requires different approaches and cell types like iPSC-derived oligodendrocytes, Schwann cells 
and/or astrocytes or even a co-culture or 3-dimensional in vitro culture system to obtain 
meaningful and disease-relevant results (Shaltouki et al., 2013; Douvaras et al., 2014; Kim et al., 
2017; reviewed in: McComish and Caldwell, 2018).  
In summary we provide a valuable dataset of more than 160 MND-related transcripts of different 
patient-derived biosamples, which can be employed to preselect a proper cellular model to 
potentially decipher molecular mechanism with pathophysiological relevance and screening for 
novel therapeutic targets in various types of MNDs.  
 
Material and Methods 
Isolation of primary cells 
The study has been approved by the Ethics Committee of the University of Tübingen 
(598/2011BO1). Informed consent was obtained from all participants.  
Fibroblasts were obtained from skin biopsies of two healthy individuals (Donor 1: age: 46, gender: 
female / Donor 2: age: 37 gender: female). Skin tissue was dissected and cultivated in a 25 cm2 
tissue culture flask containing Dulbecco's modified eagle's medium (DMEM) high glucose (Life 
technologies) with 10% fetal bovine serum (FBS, Life technologies) (fibroblast medium) for 10 
days at 37 °C and 5% CO2. Fibroblast expansion was achieved by medium change every 2-3 days.  
PBMCs were isolated from whole blood of the same healthy donors as fibroblasts using a classical 
density gradient centrifugation with Ficoll (Ficoll Paque-PLUS, GE Healthcare) according to 
manufacturer’s guidelines.    
Transformation of PBMCs to lymphoblasts 
Immortalized lymphoblast cell lines were generated by infection of PBMCs (mainly B 
lymphocytes) using the EBV (Pelloquin et al., 1986). In brief, separated PBMCs were resuspended 
in 2 ml sterile EBV-containing supernatant of B95-8 cells and incubated for 30 min at 40°C. EBV-
transformed lymphocytes (lymphoblasts) were cultivated in RPMI medium (Sigma-Aldrich) 
containing 20% FBS, 1% Penicillin/Streptomycin (Biochrom), 1 µg/ml Cyclosporin A (Sigma-
Aldrich), 1mM sodium pyruvate (Sigma-Aldrich), 20mM HEPES (Sigma-Aldrich) and 1% L-
glutamine (Merck). Lymphoblasts were frozen in cryopreservation medium containing of 90% 
FBS supplemented with 10% DMSO (Sigma-Aldrich).  
Reprogramming of fibroblasts to iPSCs 
Reprogramming was achieved by electroporation of 1x105 fibroblasts with 1µg of episomal 
plasmids (pCXLE-hUL, pCXLE-hSK and pCXLE-hOCT4) as described by (Okita et al., 2011). 1 day 
after electroporation fibroblast growth factor-2 (FGF-2, 2 ng/mL, Peprotech) was supplemented 
to the fibroblast media. The following day cells were cultivated in Essential 8 (E8) medium 
supplemented with 100 µM sodium butyrate (Sigma-Aldrich) with media change every other day. 
Approx. 3-4 weeks after electroporation iPSC colonies were manually picked and further 
expanded on Matrigel-coated well plates. Splitting and replating of iPSCs was achieved by adding 
PBS/EDTA (0.02% EDTA in PBS). iPSCs were genomically and functionally analyzed according to 
(Hauser et al., 2016b). 
Differentiation of iPSCs to cortical neurons 
iPSCs were differentiated to neurons of cortical layer V and VI according to published protocols 
with minor modifications (Shi et al., 2012; Rehbach et al., 2019). Briefly, iPSCs were seeded at a 
density of 3 x 105 cells per cm2 in E8 medium supplemented with 10 µM Y-27632 (Selleckchem). 
Neural induction was obtained by supplementation of dual SMAD inhibitors (10 µM SB431542 
(Sigma-Aldrich) and 500 nM LDN-193189 (Sigma-Aldrich)) to 3N medium for 10 days. On day 10, 
cells were split in a 1:3 ratio and further expanded in 3N medium including 20 ng/ml FGF-2 for 2 
days. Until day 27, cells were cultivated in 3N medium with media change every other day. On 
day 27, cells were dissociated using Accutase (Sigma-Aldrich) and replated at a density of ~ 8 x 
105 cells per cm2. The following day, 10 µM PD0325901 (Tocris) and 10 µM DAPT (Sigma Aldrich) 
was added to 3N medium with an additional media change at day 30. From day 32 onwards 3N 
medium was changed every other day and RNA of cortical neurons was isolated at day 37 of 
differentiation.  
RNA-Sequencing analysis 
RNA isolation of cells (PBMCs, lymphoblasts, fibroblasts, iPSCs, iPSC-derived cortical neurons) 
was performed by using the RNeasy Mini Kit (Qiagen) according to the manufacturer’s guidelines. 
Further purification of isolated RNA was achieved with TruSeq mRNA v2Kit (polyA) (Illumina). 
RNA samples were sequenced on a HiSeq2500 (Illumina) by DeCODE genetics (Reykjavik, Iceland). 
For further expression analysis and to calculate the sample similarity a multi-dimensional scaling 
(MDS) plot of all RNA-Seq samples was prepared. For comparison of 138 spasticity-related genes, 
RPKMs (Reads Per Kilobase Million) for each transcript and cell type were calculated. Images were 
generated by using GraphPad Prism. 
qRT-PCR validation 
500 ng isolated RNA of each sample was reverse-transcribed to cDNA by using the RevertAid First 
Strand cDNA Synthesis Kit (Thermo Fisher Scientific) according to manufacturer’s instructions. 
Real-time qPCR was performed in triplicates by adding 2 µl primer pairs (2 µM) and 5 µl SYBR 
Green Select Master Mix (Applied Biosystems) to 3 µl cDNA (1.25 ng/µl).  
For amplification the following primers were used: 
Primer Forward sequence Reverse sequence 
ATL-1 / SPG3 CAGTCCAAGTCCTCATTGTC AATCAACTGATTCCTGGTTGTA 
BSCL2 / SPG17 TTCTACTACAGGACCGACTG CAGCTCAAGCTCTAAGGTAAC 
CYP7B1 / SPG5 CAGTTCTTCTTGGTGGAAAGTA TGCAACTGACTGATGCTAAA 
FA2H / SPG35 TGGGAGAGAAGTACGATGAG GGGACACTGTACCAGACA 
GAPDH  TCACCAGGGCTGCTTTTAAC GACAAGCTTCCCGTTCTCAG 
KIF5A / SPG10 GTCACCAACATGAATGAACAC CCAGGTCCACCAGATACA 
REEP1 / SPG31 CCTTTGTTGGTTTCCATTCTAT CAGACAATCATCGATTTCCTTT 
SPAST / SPG4 ATAGTTACAGGACAAGGTGAAC ACGTCCGTTTGTGACTTG 
SPG7 / SPG7 CAGGATTCTTTGGAAATGCC CCATCTTCCCATCCACAAT 
SPG11 / SPG11 GTATTTCAGGCAACACCCA GGCTTTCCAAGACCTATCAAT 
TBP CTTCGGAGAGTTCTGGGATTG CACGAAGTGCAATGGTCTTTAG 
ZFYVE26 / SPG15 ATACAGCAGAGCAGCAAC TCTGTAAGAGCTTGAGAACATC 
 
Real-time qPCR was performed on the Viia7 Real-Time PCR System (Applied Biosystems) applying 
the following qRT-PCR program: 50°C for 2min, 95°C for 2min, 40 cycles of 95°C for 1s, 60°C for 
30s and 72°C for 5s, followed by 95°C for 15s, 60°C for 1min and 95°C for 15s. Melting curve 
analysis confirmed the specificity of the PCR products. Further analysis was performed with 
QuantStudio Software V1.3 (Thermo Fisher Scientific) and visualized using GraphPad Prism. 
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Figures 
Figure 1 
 
Fig. 1. Overview of patient-relevant cell types used for RNA-Sequencing profiling. (A) Peripheral 
blood mononuclear cells (PBMC) were isolated from whole blood and immortalized to 
lymphoblasts (LB) by EBV (Epstein-Barr Virus)-transformation. Fibroblasts (F) were 
isolated from skin biopsies, reprogrammed to induced pluripotent stem cells (iPSCs) and 
further differentiated to cortical neurons (CN). (B) Multidimensional scaling plot (MDS, 3-
dimensional) of all analyzed RNA-Seq samples. (C) RPKM (reads per kilobase million) 
values of cell type-specific markers of the two healthy donors (1 and 2). 
  
Figure 2 
 
Fig. 2. Expression profiling of MND-related transcripts in RPKMs (reads per kilobase million) in 
five cell types derived from healthy donors (1 and 2). Alphabetic order of MND-related 
genes with (A) RPKMs ranging from 0 – 105 and with (B) RPKMs with at least one value > 
105. HSP transcripts are encoded as: gene name / SPG type. Other MND-related 
transcripts are encoded as: gene name. RPKMs below 0.5 were set as 0. PBMC – 
peripheral blood mononuclear cells, LB – lymphoblasts, F – fibroblasts, iPSC – induced 
pluripotent stem cells, CN – iPSC-derived cortical neurons.  
 
  
Figure 3 
 
Fig. 3. Expression of (A) HSP-, (B) ALS- and (C) SMA-related transcripts classified according to the 
cell type showing the highest expression. Mean value of two donors were calculated for 
each gene, cell type and disease and the highest value of each gene was set to 100%. For 
each cell type relative values (in %) are given for the respective gene. Grouping per cell 
type is shown from high to low RPKMs. HSP transcripts are encoded as: gene name / SPG 
type. Other MND-related transcripts are encoded as: gene name. PBMC – peripheral 
blood mononuclear cells, LB – lymphoblasts, F – fibroblasts, iPSC – induced pluripotent 
stem cells, CN – iPSC-derived cortical neurons, RPKMs – reads per kilobase million. 
 
 
  
Figure 4 
 
Fig. 4. qRT-PCR validation of transcripts of the 10 most common subtypes of HSP (A). ΔCT-values 
of iPSC-derived cortical neurons of donor 1 (CN-1) normalized to the housekeeping genes 
GAPDH and TBP (B – K) Relative values (ΔΔCT) of all analyzed cell types and transcripts 
normalized to the housekeeping genes GAPDH and TBP and to the cell line with highest 
transcript expression value (set to 1) n.d. – not detectable, PBMC – peripheral blood 
mononuclear cells, LB – lymphoblasts, F – fibroblasts, iPSC – induced pluripotent stem 
cells, CN – iPSC-derived cortical neurons. 
 
 Figure 5 
 
Fig. 5. Simplified overview of  HSP, ALS and SMA analyzed disease genes. (A) HSP genes are listed 
according to their SPG number (1-80). (B) ALS and (C) SMA genes are ordered 
alphabetically. Color defines the cell type with the highest expression for each gene. n.d. 
– not detectable, PBMC – peripheral blood mononuclear cells, LB – lymphoblasts, F – 
fibroblasts, iPSC – induced pluripotent stem cells, CN – iPSC-derived cortical neurons, 
unknown gene – only loci identified. 
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